Allogeneic human plasma and platelet derived products and uses thereof

This application is a continuation application of International Application No. PCT/US25/17819 filed on Feb. 28, 2025, which claims the benefit of U.S. Provisional Application 63/559,536, filed Feb. 29, 2024, and U.S. Provisional Application 63/722,936, filed Nov. 20, 2024, the contents of each are hereby incorporated by reference.

Painful joint conditions are commonly occurring and debilitating with many different etiologies. These diseases and the symptoms of pain and reduced function can be due to problems with the bone, nerves and connective tissue. Orthopedic and nervous tissue injuries such as painful lumbar radiculopathy, osteoarthritis, tendon or ligament injuries (such as to the rotator cuff), nerve injury (such as carpal tunnel, spinal cord or other traumatic nerve injury), and chemotherapy-induced peripheral neuropathy cause pain and disability across many demographic groups (Centeno, J Exp Orthop. 2017 Nov. 25; 4(1):38; Peng B Y, et al., J Biomed Sci. 2023; 30(1):77; Peng Y, et al., P M R. 2023; 15(12):1643-1653; Kawabata S, et al., Int J Mol Sci. 2023; 24(8):7677; Zunino, G. et al., Society of Neuroscience. Nov. 11-15, 2023, Washington DC). In particular, low back pain is one of the highest burden of diseases, and in 2016 was the leading cause of disability-adjusted-life-years (DALY) in 2016 (Mokdad A H, et al., JAMA. 2018 Apr. 10; 319(14):1444-1472). Painful lumbosacral radiculopathy (PLSR) is a disease that typically involves compression of the lumbar spinal nerve root, and it can manifest in several ways such as weakness, pain, or numbness. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first line of treatment, providing short-term pain relief (van der Gaag W H, et al., Cochrane Database Syst Rev. 2020 Apr. 16; 4(4):CD013581), but may increase the risk of developing chronic pain (Parisien M, et al., Sci Transl Med. 2022 May 11; 14(644):eabj9954C). Steroids are often used to treat PLSR, despite no proven efficacy and significant side effects, including bone loss and increased spinal fracture risks. Opioids are also used to manage PLSR, but do not treat the cause and have significant addictive potential.

Autologous preparations of platelet rich plasma and human platelet lysate has been shown to be a promising regenerative therapy, which is attributed to the presence of cytokines and growth factors. Platelet rich plasma and human platelet lysates may be used locally to treat orthopedic, tendon or nerve injuries. Autologous platelet lysate has been administered epidurally to treat PLSR and was shown to reduce lumbar radicular pain (Centeno, J Exp Orthop. 2017 Nov. 25; 4(1):38). While the results with the autologous platelets demonstrate the potential pharmacological activity of a regenerative medicine in PLSR, there is inherent variability in the process of preparing the platelet lysate. The biological activity and identity of the autologous preparation is unknown, and there may be variability in the potency between individuals.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFb1, TGFb2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising at least one of albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFb1, TGFb2, BDNF, VEGF, FGF, EGF and HGF, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising at least one of albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFb1, TGFb2, VEGF, FGF, EGF and HGF, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFb1, TGFb2, VEGF, FGF, EGF and HGF, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising fibrinogen; and (b) human platelet proteins comprising PDGF-AB wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising fibrinogen, human serum albumin and immunoglobulin; and (b) human platelet proteins comprising PDGF-AB, TGF-β, VEGF, EGF, FGF and HGF, wherein: (i) the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, (ii) the concentration of fibrinogen is about 0.25 mg/mL to about 5 mg/mL, (iii) the concentration of human serum albumin is about 60% to about 70% w/w total protein, (iv) the concentration of immunoglobulin is about 10% to about 20% w/w total protein, and (v) the concentration of PDGF-AB is about 5 ng/mL to about 200 ng/mL.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising: (a) human plasma proteins comprising fibrinogen at a concentration of about 1 mg/mL to about 2 mg/mL, and (b) human platelet proteins comprising about 20 to about 70 μg/mL PDGF-AB, wherein the total protein concentration is about 50 mg/mL to about 160 mg/mL. In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising: (a) human plasma proteins comprising fibrinogen at a concentration of about 0.77 mg/mL, and (b) human platelet proteins comprising about 21 to about 67 μg/mL PDGF-AB, wherein the total protein concentration is about 56 mg/mL to about 156 mg/mL. In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product as characterized in Examples 11 and 14.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising: (a) human plasma proteins comprising about 1 mg/mL to about 2 mg/mL fibrinogen, and about 60% to about 70% w/w albumin, about 10% to about 20% w/w immunoglobulin, and (b) human platelet proteins comprising about 50 to about 60 ng/mL PDGF-AB, about 350 to about 450 ng/mL TGF-β, about 450 to about 650 pg/mL VEGF, about 1000 to about 3000 pg/mL EGF, about 750 to about 1000 pg/mL FGF, and about 300 to about 800 pg/mL HGF, wherein the total protein concentration is about 50 mg/mL to about 160 mg/mL, wherein the total protein concentration is about 100 mg/mL to about 150 mg/mL. In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product as characterized in Example 31.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising at least one of albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising at least one of albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In other aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising fibrinogen, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, or about 1 mg/mL to about 5 mg/mL; and (b) human platelet proteins comprising PDGF-AB, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL. In some embodiments, the total protein concentration is less than or about 250 mg/mL. In some embodiments, the total protein concentration is about 100 mg/mL to about 250 mg/mL.

In some embodiments, the composition has a viscosity of 50 cP or less. In some embodiments, the composition comprises a viscosity of less than 25 cP, less than 20 cP, less than 15 cP, or less than 10 cP. In some embodiments, the viscosity is about 1 to about 5 cP, 5 to about 10 cP, about 10 to about 15 cP, or about 15 to about 20 cP.

In some embodiments, the composition has a pH of about 4.5 to about 8.5. In some embodiments, the composition has an osmolality of about 200 to about 500 mOsmo/kg.

In some embodiments, the concentration of albumin is about 100 to about 1,400 mg/mL. In some embodiments, the concentration of albumin is greater than or about 40% w/w. In some embodiments, albumin is human serum albumin. In some embodiments, the concentration of albumin is about 60% to about 70% w/w.

In some embodiments, the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, or about 1 mg/mL to about 5 mg/mL.

In some embodiments, the globulins comprise immunoglobulins. In some embodiments, the concentration of immunoglobulins is greater than or about 20% w/w. In some embodiments, the concentration of immunoglobulins is about 10% to about 20% w/w. In some embodiments, the globulins comprise alpha-2-macroglobulin (A2M). In some embodiments, the concentration of A2M is greater than or about 200 mg/mL.

In some embodiments, the concentration of albumin and/or immunoglobulin is determined by capillary electrophoresis sodium dodecyl sulfate (CE-SDS), enzyme-linked immunosorbent assay (ELISA), size exclusion high performance liquid chromatography (SEC-HPLC), or SDS polyacrylamide gel electrophoresis (SDS-PAGE).

In some embodiments, the concentration of PDGF-AB is about 5 ng/mL to about 200 ng/mL. In some embodiments, the concentration of PDGF-AB is about 20 ng/mL to about 160 ng/mL, about 20 ng/mL to about 40 ng/mL, about 40 ng/mL to about 80 ng/mL, or about 80 ng/mL to about 160 ng/mL.

In some embodiments, the human platelet proteins comprise one or more of PDGF-AB, PDGF-AA, PDGF-BB, TGF-β1, TGF-β2, VEGF, FGF, EGF, and HGF. In some embodiments, the concentration of TGF-β is about 50 ng/mL to about 1000 ng/mL, the concentration of VEGF is about 50 pg/mL to about 1500 pg/mL, the concentration of EGF is about 100 pg/mL to about 6000 pg/mL, the concentration of FGF is about 100 pg/mL to about 3000 pg/mL, and/or the concentration of HGF is about 25 pg/mL to about 2500 pg/mL. In some embodiments, (i) the concentration of TGF-β is about 175 ng/mL to about 225 ng/mL, about 350 ng/mL to about 450 ng/mL, or about 700 ng/mL to about 900 ng/mL; (ii) the concentration of VEGF is about 225 pg/mL to about 325 pg/mL, 450 pg/mL to about 650 pg/mL, or about 900 pg/mL to about 1300 pg/mL; (iii) the concentration of EGF is about 500 pg/mL to about 1500 pg/mL, about 1000 pg/mL to about 3000 pg/mL, or about 2000 pg/mL to about 6000 pg/mL; (iv) the concentration of FGF is about 350 pg/mL to about 500 pg/mL, about 700 pg/mL to about 1000 pg/mL, or about 1400 pg/mL to about 2000 pg/mL; (v) the concentration of HGF is about 125 pg/mL to about 425 pg/mL, about 250 pg/mL to about 850 pg/mL, or about 500 pg/mL to about 1700 pg/mL; or (vi) any combination of (i)-(v).

In some embodiments, the total protein concentration is about 50 mg/mL to about 80 mg/mL, the fibrinogen concentration is about 0.5 mg/mL to about 1 mg/mL, the PDGF-AB concentration is about 20 ng/mL to about 40 ng/mL, the TGF-β concentration is about 150 ng/mL to about 300 ng/mL, the VEGF concentration is about 200 pg/mL to about 400 pg/mL, the EGF concentration is about 1000 pg/mL to about 2000 pg/mL, the FGF concentration is about 300 pg/mL to about 600 pg/mL, and the HGF concentration is about 150 pg/mL to about 300 pg/mL. In some embodiments, the total protein concentration is about 80 mg/mL to about 160 mg/mL, the fibrinogen concentration is about 1 mg/mL to about 2 mg/mL, the PDGF-AB concentration is about 40 ng/mL to about 80 ng/mL, the TGF-β concentration is about 350 ng/mL to about 450 ng/mL, the VEGF concentration is about 400 pg/mL to about 800 pg/mL, the EGF concentration is about 2000 pg/mL to about 4000 pg/mL, the FGF concentration is about 600 pg/mL to about 1200 pg/mL, and the HGF concentration is about 300 pg/mL to about 1000 pg/mL. In some embodiments, the total protein concentration is about 160 mg/mL to about 320 mg/mL, the fibrinogen concentration is about 2 mg/mL to about 5 mg/mL, the PDGF-AB concentration is about 80 ng/mL to about 160 ng/mL, the TGF-β concentration is about 500 ng/mL to about 1000 ng/mL, the VEGF concentration is about 800 pg/mL to about 1500 pg/mL, the EGF concentration is about 4000 pg/mL to about 6000 pg/mL, the FGF concentration is about 1200 pg/mL to about 3000 pg/mL, and the HGF concentration is about 1000 pg/mL to about 2500 pg/mL.

In some embodiments, the composition comprises an anti-inflammatory protein. In some embodiments, the platelet proteins comprise an anti-inflammatory protein. In some embodiments, the anti-inflammatory protein is selected from interleukin 1 (IL-1), receptor antagonist protein (IRAP), IL-10, TIMP-1, and any combination thereof. In some embodiments, the anti-inflammatory proteins comprise at least two of IL-1, IRAP, IL-10 and TIMP-1. In some embodiments, the anti-inflammatory proteins comprise at least three of IL-1, IRAP, IL-10 and TIMP-1. In some embodiments, the anti-inflammatory proteins comprise IL-1, IRAP, IL-10 and TIMP-1. In some embodiments, the composition comprises an antioxidant protein. In some embodiments, the platelet proteins comprise an antioxidant protein. In some embodiments, the antioxidant protein is selected from glutathione S-transferase, glutathione peroxide, catalase, and any combination thereof. In some embodiments, the antioxidant proteins comprise glutathione S-transferase, glutathione peroxide, and catalase. In some embodiments, the antioxidant proteins comprise any two of glutathione S-transferase, glutathione peroxide, and catalase.

In some embodiments, the pharmaceutical composition comprises one or more cytokines selected from IL-5, IL-1b, IL-6, IL-1Ra, IL-10, IL-13, TNFα, IL-8, IL-12p40, and MCP-1.

In some embodiments, the composition comprises a buffer which maintains plasma proteins in solution. In some embodiments, the buffer comprises citrate or phosphate buffer comprising NaCl.

In some embodiments, the composition forms a depot at a site of injection. In some embodiments, the composition comprises one or more plasma proteins, e.g., fibrinogen, capable of forming a matrix following administration to a subject in vivo.

In some embodiments, the composition is formulated for epidural injection. In some embodiments, the composition is formulated for intraarticular injection. In some embodiments, the composition is formulated for intrathecal injection. In some embodiments, the composition is formulated for intramuscular injection. In some embodiments, the composition is formulated for intravitreal injection. In some embodiments, the composition is formulated for subretinal injection. In some embodiments, the composition is formulated for suprachoroidal injection. In some embodiments, the composition is formulated for systemic injection. In some embodiments, the composition is formulated for intravenous injection. In some embodiments, the composition is formulated for intraosseous injection. In some embodiments, the composition is formulated for local administration.

In some aspects, the disclosure provides a method for treating pain in a subject, comprising administering to the subject a pharmaceutical composition described herein.

In some aspects, the disclosure provides a method for treating an orthopedic indication or injury in a subject, comprising administering to the subject a pharmaceutical composition described herein. In some aspects, the disclosure provides use of a pharmaceutical composition described herein for treating an orthopedic indication or injury in a subject.

In some embodiments, the orthopedic indication or injury is selected from painful lumbar radiculopathy, a spinal cord injury, osteoarthritis, ligament laxity, a rotator cuff injury, and a muscle injury. In some embodiments, the pharmaceutical composition is administered locally. In some embodiments, local administration is epidural, intrathecal, intra-articular, intramuscular, direct injection into a tendon, or direction injection into a ligament.

In some aspects, the disclosure provides a method for treating painful lumbar radiculopathy in a subject, comprising administering to the subject a pharmaceutical composition formulated for epidural injection described herein. In some embodiments, the method comprises x-ray guided needle injection.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for epidural injection described herein for treating painful lumbar radiculopathy in a subject. In some embodiments, the use comprises x-ray guided needle injection.

In some aspects, the disclosure provides a method for treating a spinal cord injury in a subject, comprising administering to the subject a pharmaceutical composition formulated for intrathecal injection described herein.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for intrathecal injection described herein for treating a spinal cord injury in a subject.

In some aspects, the disclosure provides a method for treating osteoarthritis in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraarticular injection described herein.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for intraarticular injection described herein for treating osteoarthritis in a subject.

In some aspects, the disclosure provides a method for treating chemotherapy-induced peripheral neuropathy (CIPN), comprising administering to the subject a pharmaceutical composition described herein. In some embodiments, administering is systemic administration. In some embodiments, systemic administration is intravenous administration.

In some aspects, the disclosure provides a method for treating an ophthalmic condition or disease in a subject, comprising administering a pharmaceutical composition described herein.

In some aspects, the disclosure provides use of a pharmaceutical composition described herein for treating chemotherapy-induced peripheral neuropathy (CIPN). In some embodiments, the pharmaceutical composition is formulated for systemic administration. In some embodiments, systemic administration is intravenous administration.

In some embodiments, the pharmaceutical composition is diluted to a desired dose.

In some aspects, the disclosure provides a kit comprising a container comprising a pharmaceutical composition described herein and instructions for treating a subject with an orthopedic indication or injury. In some embodiments, orthopedic indication or injury is selected from painful lumbar radiculopathy, a spinal cord injury, osteoarthritis, ligament laxity, a rotator cuff injury, and a muscle injury. In some embodiments, the instructions comprise diluting the pharmaceutical composition to an appropriate dose. In some embodiments, the instructions comprise injecting the pharmaceutical composition into a site appropriate for the orthopedic indication or injury.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition described herein, the method comprising:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition described herein, the method comprising:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) centrifuging and filtering the platelet suspension; (c) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (d) separating the platelet extract from cell debris comprising centrifuging and filtering the platelet extract, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins; (e) filtering the purified platelet extract; and (f) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product, wherein the method comprises:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, wherein:

(i) the plasma proteins comprise albumin, globulins, and fibrinogen; and (ii) the platelet proteins comprise PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, b-FGF, EGF and HGF,

(d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product, wherein the method comprises:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, wherein:

(i) the plasma proteins comprise albumin, globulins, and fibrinogen; and (ii) the platelet proteins comprise PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, VEGF, b-FGF, EGF and HGF,

(d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product, wherein the method comprises:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, wherein:

(i) the plasma proteins comprise at least one of albumin, globulins, and fibrinogen; and (ii) the platelet proteins comprise at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, b-FGF, EGF and HGF,

(d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product, wherein the method comprises:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, wherein:

(i) the plasma proteins comprise at least one of albumin, globulins, and fibrinogen; and (ii) the platelet proteins comprise at least one of PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, VEGF, b-FGF, EGF and HGF,

(d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some aspects, the disclosure provides a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product, wherein the method comprises:

(a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins; (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins; (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, wherein:

(i) the plasma proteins comprise at least one of albumin, globulins, and fibrinogen; and (ii) the platelet proteins comprise at least PDGF-AB,

(d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, the platelet suspension is from one or more donor human subjects at an age of 16 to 65 years old. In some embodiments, the platelet suspension is from one or more donor human subjects at an age of 16 to 35 years old. In some embodiments, the platelet suspension is from 10 or more donor human subjects. In some embodiments, the platelet suspension is from whole-blood. In some embodiments, the platelet suspension is from apheresis. In some embodiments, the platelet suspension has been treated with an anti-coagulant, optionally wherein the anti-coagulant is selected from an acid-citrate-dextrose solution, citrate, and heparin.

In some embodiments, step (b) comprises (i) applying at least one freeze-thaw cycle, (ii) contacting the platelet suspension with a detergent, (iii) applying osmotic pressure, (iv) sonication, (v) electroporation, (vi) high pressure microfluidics, or (vii) any combination of (i)-(vi).

In some embodiments, step (b) comprises applying at least one freeze-thaw cycle to the platelet suspension. In some embodiments, the at least one freeze-thaw cycle comprises freezing the source at about −210° C. to about −80° C. and thawing the platelet suspension at about 2-8° C., 15-25° C., or up to 37° C. In some embodiments, the at least one freeze-thaw cycle is three freeze-thaw cycles.

In some embodiments, step (b) comprises contacting the platelet suspension with a detergent to extract platelet proteins from platelets. In some embodiments, the detergent is an anionic detergent, a non-ionic detergent, a cationic detergent, or a zwitterionic detergent. In some embodiments, the detergent is non-denaturing, a mild lysis agent, or a strong lysis agent. In some embodiments, the detergent is sodium dodecyl sulphate (SDS), ethyl trimethyl ammonium bromide, Triton X-45, Triton X-100, Triton X-114, NP-40, Tween 20, Tween 80, CHAPS, or CHAPSO. In some embodiments, the platelet suspension is incubated with the detergent under continuous mixing or gentle rocking for about 10 minutes to about 24 hours, optionally at a temperature of about 4° C. to about 40° C.

In some embodiments, step (b) comprises applying osmotic pressure to the platelet suspension. In some embodiments, osmotic pressure is increased by salts, sugars, and/or buffers. In some embodiments, osmotic pressure is decreased by water, salts, sugars, and/or buffers. In some embodiments, osmotic pressure is from about 0.01 to about 1,000 mOsm/kg.

In some embodiments, the method comprises inactivating and/or removing or reducing viruses. In some embodiments, inactivating and/or removing or reducing viruses occurs in step (b), wherein conditions appropriate to extract platelet proteins inactivate viruses. In some embodiments, inactivating and/or removing or reducing viruses occurs after step (b). In some embodiments, inactivating viruses comprises heat-inactivation, ultraviolet radiation, chemical treatment, or low pH treatment. In some embodiments, removing or reducing viruses comprises nanofiltration or chromatography.

In some embodiments, step (b) occurs in the absence of a clotting agent. In some embodiments, step (b) does not include removing a clot.

In some embodiments, step (c) comprises micro-filtration, depth-filtration, or centrifugation.

In some embodiments, step (d) comprises tangential flow filtration of the purified platelet extract, optionally wherein a membrane for tangential flow filtration has a size of about 1 KDa to about 500 KDa. In some embodiments, step (d) comprises using spin filters to concentrate the purified platelet extract.

In some embodiments, the platelet suspension is diluted in a solution prior to step (b). In some embodiments, the purified platelet extract is diluted in a solution prior to step (d). In some embodiments, the solution is a buffer, optionally phosphate buffered saline (PBS) or a buffer comprising citrate.

In some embodiments, the metho comprises step (e) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, step (e) comprises passing the allogeneic human plasma and platelet derived product through a filter of about 0.1 mm to about 0.22 mm.

In some embodiments, the method comprises reducing or removing blood cells from the platelet suspension prior to step (b). In some embodiments, blood cells comprise red blood cells and white blood cells. In some embodiments, white blood cells are reduced by about a 5-6 log reduction. In some embodiments, reducing or removing blood cells comprises passing the platelet suspension through a filter at a temperature of about 2° C. to about 8° C. In some embodiments, the filter is about 0.1 mm to about 40 mm.

In some embodiments, step (b) comprises maintaining the platelet suspension in conditions sufficient to maintain plasma proteins in solution.

In some embodiments, the human allogeneic plasma and platelet derived product is diluted to a dosage form. In some embodiments, the dosage form is for epidural injection, intramuscular injection, intrathecal injection, intraarticular injection, direct injection to a tendon, or direct injection to a ligament.

In some embodiments, the total protein concentration of the pharmaceutical composition is greater than 50 mg/mL and less than or about 500 mg/mL. In some embodiments, the total protein concentration is less than or about 250 mg/mL. In some embodiments, the total protein concentration is about 100 mg/mL to about 250 mg/mL.

In some embodiments, the pharmaceutical composition has a viscosity of 50 cP or less. In some embodiments, the pharmaceutical composition comprises a viscosity of less than 25 cP, less than 20 cP, less than 15 cP, or less than 10 cP. In some embodiments, the viscosity is about 1 to about 5 cP, 5 to about 10 cP, about 10 to about 15 cP, or about 15 to about 20 cP.

In some embodiments, the pharmaceutical composition has a pH of about 4.5 to about 8.5. In some embodiments, the composition has an osmolality of about 200 to about 500 mOsmo/kg.

In some embodiments, the concentration of albumin is about 100 to about 1,400 mg/mL. In some embodiments, the concentration of albumin is greater than or about 40% w/w. In some embodiments, albumin is human serum albumin.

In some embodiments, the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, or about 1 mg/mL to about 5 mg/mL.

In some embodiments, the globulins comprise immunoglobulins. In some embodiments, the concentration of immunoglobulins is greater than or about 20% w/w. In some embodiments, the globulins comprise alpha-2-macroglobulin (A2M). In some embodiments, the concentration of A2M is greater than or about 200 mg/mL.

In some embodiments, the platelet proteins comprise an anti-inflammatory protein. In some embodiments, the anti-inflammatory protein is selected from interleukin 1 (IL-1), receptor antagonist protein (IRAP), IL-10, TIMP-1, and any combination thereof. In some embodiments, the platelet proteins comprise an antioxidant protein. In some embodiments, the antioxidant protein is selected from glutathione S-transferase, glutathione peroxide, catalase, and any combination thereof.

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product produced by any of the methods described herein. In some embodiments, the composition forms a depot at a site of injection. In some embodiments, the composition is formulated for epidural injection. In some embodiments, the composition is formulated for intraarticular injection. In some embodiments, the composition is formulated for intrathecal injection. In some embodiments, the composition is formulated for intramuscular injection.

In some aspects, the disclosure provides a method for treating an orthopedic indication or injury in a subject, comprising administering to the subject a pharmaceutical composition described herein. In some aspects, the disclosure provides use of a pharmaceutical composition described herein for treating an orthopedic indication or injury in a subject.

In some embodiments, the orthopedic indication or injury is selected from painful lumbar radiculopathy, a spinal cord injury, osteoarthritis, ligament laxity, a rotator cuff injury, and a muscle injury. In some embodiments, the pharmaceutical composition is administered locally. In some embodiments, local administration is epidural, intrathecal, intra-articular, intramuscular, direct injection into a tendon, or direction injection into a ligament.

In some aspects, the disclosure provides a method for treating painful lumbar radiculopathy in a subject, comprising administering to the subject a pharmaceutical composition formulated for epidural injection described herein. In some embodiments, the method comprises x-ray guided needle injection.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for epidural injection described herein for treating painful lumbar radiculopathy in a subject. In some embodiments, the use comprises x-ray guided needle injection.

In some aspects, the disclosure provides a method for treating a spinal cord injury in a subject, comprising administering to the subject a pharmaceutical composition formulated for intrathecal injection described herein.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for intrathecal injection described herein for treating a spinal cord injury in a subject.

In some aspects, the disclosure provides a method for treating osteoarthritis in a subject, comprising administering to the subject a pharmaceutical composition formulated for intraarticular injection described herein.

In some aspects, the disclosure provides use of a pharmaceutical composition formulated for intraarticular injection described herein for treating osteoarthritis in a subject.

In some aspects, the disclosure provides a method for treating chemotherapy-induced peripheral neuropathy (CIPN), comprising administering to the subject a pharmaceutical composition described herein. In some embodiments, administering is systemic administration. In some embodiments, systemic administration is intravenous administration.

In some aspects, the disclosure provides use of a pharmaceutical composition described herein for treating chemotherapy-induced peripheral neuropathy (CIPN). In some embodiments, the pharmaceutical composition is formulated for systemic administration. In some embodiments, systemic administration is intravenous administration.

In some embodiments, the pharmaceutical composition is diluted to a desired dose.

In some aspects, the disclosure provides a kit comprising a container comprising a pharmaceutical composition described herein and instructions for treating a subject with an orthopedic indication or injury. In some embodiments, orthopedic indication or injury is selected from painful lumbar radiculopathy, a spinal cord injury, osteoarthritis, ligament laxity, a rotator cuff injury, and a muscle injury. In some embodiments, the instructions comprise diluting the pharmaceutical composition to an appropriate dose. In some embodiments, the instructions comprise injecting the pharmaceutical composition into a site appropriate for the orthopedic indication or injury.

FIGS. 1 - 9 provide exemplary processes for producing allogeneic human plasma and platelet derived products (AHPPDP).

FIG. 10 provides a sodium dodecyl sulfate-polyacrylamide gel electrophoreses (SDS-PAGE) gel of soluble protein following extraction of platelet proteins via different extraction methods. Lane 1 shows total soluble protein following extraction via hypo-osmotic 1 conditions. Lane 2 shows total soluble protein following extraction via hypo-osmotic 2 conditions. Lane 3 shows total soluble protein following extraction via hypo-osmotic 3 conditions. Lane 4 shows total soluble protein following extraction via hyper-osmotic conditions. Lane 5 shows total soluble protein following extraction via detergent. Lane 6 shows total soluble protein following extraction via 3 freeze-thaw cycles.

FIG. 11 provides a graph showing the activity of PDGF in allogenic human plasma and platelet derived product in a reporter cell assay.

FIG. 12 provides an SDS-PAGE gel showing protein of sterile filtered platelet extract samples. Lane 1 shows extracted platelet proteins before sterile filtration. Lane 2a shows protein in the soluble layer after centrifugation at 15,000×g. Lane 2c shows protein in the cell pellet after centrifugation at 15,000×g. Lane 3 shows soluble protein after centrifugation at 15,000×g and sterile filtration with a 0.2 μm polyethansulfone (PES) filter. Lane Mw depicts the molecular weight ladder. Lane IgG depicts a representative monoclonal antibody for IgG at 1 mg/mL. Lane HSA depicts 1 mg/mL pure human serum albumin. Lane GF depicts 1 mg/mL gel filtration standard (Bio-Rad).

FIG. 13 A shows a graph depicting knee width (mm) of an arthritis rat model. 50 μg complete Freund's adjuvant (CFA) was injected in the intra-articular (IA) space of the right knee of Sprague Dawley rats to induce arthritis on Day 1 (bottom arrow). On Days −3, −1, and 2 relative CFA injection (top arrows), rats were injected with a composition comprising AHPPDP (Composition E26h) or vehicle set forth in Table 16.

FIG. 13 B shows a graph depicting knee width (mm) of an arthritis rat model. 100 pg complete Freund's adjuvant (CFA) was injected in the intra-articular (IA) space of the right knee of Sprague Dawley rats to induce arthritis on Day 1 (bottom arrow). On Days −3, −1, and 2 relative CFA injection (top arrows), rats were injected with Composition E26h or vehicle set forth in Table 16.

FIG. 14 shows a schematic of a study design for acute paclitaxel-induced peripheral neuropathy. 15 mg/kg/day paclitaxel was administered intraperitoneally (IP) once daily to animals for 5 days. A composition comprising AHPPDP at either a low dose (˜300 mg/kg; Composition F20f) or a high dose (˜600 mg/kg; Composition F20d) was administered intravenously (IV) once on Day 6 and Day 7.

FIG. 15 is a graph showing paclitaxel-induced allodynia quantified by an acetone cooling test (ACT) score. Adult male C57BL6/J mice were administered paclitaxel or vehicle. Mice were placed into von Frey chambers and allowed to acclimate for 30 minutes. 10-15 μL of acetone spray was applied onto the medial area of the plantar hind paw using 0.5 mL syringes. Responses of each animal to acetone were monitored for 20 seconds, and the score was given based on a four-point scale. Data are presented as Mean±SEM; Group 1, n=10 and Group 2, n=15. Group 2 vs Group 1: *p<0.05 (Mann-Whitney test).

FIG. 16 is a graph showing paclitaxel-induced allodynia quantified by an ACT score following intravenous administration of Composition F20f or vehicle set forth in Table 18. Data are presented as Mean±SEM; Group 1, n=10 and Group 2, n=15. Group 3 vs Group 2: *p<0.05 (Mann-Whitney test).

FIG. 17 is a graph showing paclitaxel-induced allodynia quantified by an ACT score following intravenous administration of Composition F20d or vehicle set forth in Table 18. Data are presented as Mean±SEM; Group 1, n=10 and Group 2, n=15. Group 4 vs Group 2: *p<0.05 (Mann-Whitney test).

FIG. 18 provides graphs depicting reduction of cytokine levels in THP-1 cells after induction of inflammation by lipopolysaccharide and treatment with a composition comprising AHPPDP (Composition E26f).

FIG. 19 provides graphs depicting levels of IL-1β cytokine levels in mouse plasma following treatment with paclitaxel or paclitaxel and either low dose AHPPDP (F20f) or high dose AHPPDP (F20d). BL=baseline; D5=Day 5; D8=Day 8; EP=end of study. Statistical analysis: *p<0.05 (Mann-Whitney test)

FIG. 20 provides graphs depicting CD4+ T cell response of human donor peripheral blood mononuclear cells (PBMC) after treatment with AHPPDP, keyhole limpet hemocyanin (KLH), or immunoglobulin (IVIg).

FIGS. 21 A- 21 D provide graphs depicting the concentration of PDGF as a function of increasing concentrations of AHPPDP ( FIG. 21 A ), activation of PDGFRα/β ( FIG. 21 B ), the concentration of EGF as a function of increasing concentrations of AHPPDP ( FIG. 21 C ), and activation of EGFR1 ( FIG. 21 D ) after treatment with AHPPDP (CUR-001-20L-SEP24) in human cells.

FIG. 22 provides graphs depicting reduction of cytokine levels in THP-1 cells after induction of inflammation by lipopolysaccharide and treatment with a composition comprising AHPPDP (Composition CUR-2401-6L-SEP24).

FIG. 23 provides a graph of total protein concentration of pooled whole blood following depth filtration with a polyacrylic fiber and silica, diatomaceous earth (DE) and cellulose, or cellulose filter.

FIG. 24 provides a graph of PDGF-AB concentration of pooled whole blood following depth filtration with a polyacrylic fiber and silica, diatomaceous earth (DE) and cellulose, or cellulose filter.

FIG. 25 provides a graph of PDGF-AB concentration of pooled whole blood following rinsing of a polyacrylic fiber and silica, diatomaceous earth (DE) and cellulose, or cellulose filter.

FIG. 26 provides an exemplary process for producing allogeneic human plasma and platelet derived products (AHPPDP).

The present disclosure provides compositions comprising an allogeneic human plasma and platelet derived product, along with methods of making and using the compositions, for, e.g., orthopedic indications. In some aspects, the disclosure is based in part on the discovery of a composition suitable for therapeutic uses derived from allogenic human plasma and platelets having a high concentration of platelet proteins (e.g., PDGF-AB, PDGF-AA, and/or PDGF-BB). It has been demonstrated that the methods described herein result in a composition derived from allogenic human plasma and platelets with a high concentration of both plasma proteins (e.g., albumin, globulins, and fibrinogen) and platelet proteins (e.g., PGDF-AB, PDGF-AA, and PDGF-BB). In some aspects of the disclosure, human plasma proteins are reduced in the composition while a high concentration of human platelet proteins is maintained. Without wishing to be bound by theory, a composition comprising a high concentration of human plasma and platelet derived proteins is therapeutically beneficial for conditions such as orthopedic indications. In some aspects, the disclosure provides a composition wherein the concentration of human plasma and platelet derived proteins is greater than about 50 mg/mL.

In some aspects, the disclosure provides a composition comprising a high concentration of allogenic human plasma and platelet derived proteins having a viscosity which maintains both human plasma proteins and human platelet proteins at a site of injection (e.g., a viscosity of about 10 to about 40 cP or less than about 50 cP). As therapeutics generally diffuse from a site of injection, it is believed a high viscosity allows a high protein concentration composition of the disclosure to remain at the site of injection for a period of time sufficient to provide a therapeutic effect. In some aspects, the viscosity of a high protein concentration composition of the disclosure is reduced by for example, dilution, removal of some plasma proteins, and/or inclusion of viscosity modifiers, while maintaining a high total concentration of human plasma and platelet derived proteins.

In some aspects, the disclosure provides a composition comprising a high concentration of allogeneic human plasma and platelet derived proteins and citrate. Citrate acts as a stabilizer, cryoprotectant, and anticoagulant and is often added to blood-derived products. In some aspects, methods for generating the composition comprise using one or more buffers comprising citrate. In some aspects, methods for generating the composition comprise removing citrate through, e.g., buffer exchange.

In some aspects, the compositions of the disclosure having a high concentration of allogeneic human plasma and platelet derived proteins are formulated for epidural or intraarticular injection to treat orthopedic conditions. In some aspects, the compositions of the disclosure are used for treating pain. In some aspects, the compositions of the disclosure are used for treating orthopedic and nervous tissue injuries such as painful lumbar radiculopathy, osteoarthritis, tendon or ligament injuries (such as to the rotator cuff), nerve injury (such as carpal tunnel, spinal cord or other traumatic nerve injury), and chemotherapy-induced peripheral neuropathy. In some aspects, the compositions of the disclosure are used for treating ophthalmic conditions or diseases. In some aspects, the compositions of the disclosure are used for treating open wounds or traumatic injuries. In some aspects, the compositions of the disclosure are used for treating burn wounds.

Further, the disclosure is based in part on the discovery of a method for generating the compositions of the disclosure. As described herein, it has been demonstrated that a composition comprising concentrated allogeneic human plasma and platelet derived proteins is generated by processing platelet suspensions from one or more human donor subjects to extract and concentrate platelet proteins, while also removing unwanted cells (e.g., white blood cells), cell debris, and viruses.

Allogeneic Human Plasma and Platelet Derived Product

In some aspects, the disclosure provides compositions comprising an allogeneic human plasma and platelet derived product.

As used herein, “allogeneic human plasma and platelet derived product” refers to a composition comprising human plasma proteins and human platelet proteins that is derived from one or more donors of human platelets who are not the intended recipient of a composition of the disclosure (i.e. the platelet source is allogeneic, not autologous to the human recipient). In some embodiments, the plasma and platelet derived product is obtained from platelet suspension source of one or more human donors.

As used herein, “platelet suspension” is a frozen or liquid composition of plasma and platelets obtained from one or more human blood sources. In some embodiments, the platelet suspension is obtained from a whole blood source or from apheresis of one or more human donors.

Compositions of the Disclosure

In some aspects, the disclosure provides a composition comprising an allogeneic human plasma and platelet derived product prepared by the methods described herein. In some embodiments, the composition has a viscosity and total protein concentration suitable for the administration and treatment methods disclosed herein.

Plasma and Platelet Derived Components

In some embodiments, a composition of the disclosure comprises human plasma and platelet derived proteins. In some embodiments, the plasma proteins are selected from, albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and any combination thereof. In some embodiments, the composition comprises albumin. In some embodiments, the composition comprises fibrinogen. In some embodiments, the composition comprises A2M. In some embodiments, the composition comprises immunoglobulins.

In some embodiments, the plasma proteins of the composition comprising human plasma and platelet derived proteins comprise gel-forming associated proteins. Gel-forming associated proteins are also referred to as matrix-forming proteins, which are capable of forming a gel or a matrix in vivo following administration of to a subject. Gel-forming associated proteins, such as α-2-macroglobulin (A2M) help prevent protein lysis from proteases. Others, including fibrinogen, help initiate gel formation that creates a depot at the injection site during administration by interaction with other proteins in vivo. Specifically, a matrix is formed when thrombin protease cleaves fibrinogen to form fibrin monomers. The monomers are cross-linked by certain factors, such as Factor XIIIa, to form the matrix. Accordingly, fibrinogen in the composition described herein is modified by other proteins present in a subject to form a matrix, gel, or depot at the site of injection. Gel-forming associated proteins include, but are not limited to, A2M and fibrinogen. In some embodiments, the gel-forming associated protein is A2M. In some embodiments, the gel-forming associated protein is fibrinogen. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 1 ng/mL to about 50 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 1 ng/mL to about 500 ng/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 0.5 to about 1 μg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 1 to about 100 μg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 100 to about 500 μg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 1 to about 5 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 1 to about 10 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 10 to about 25 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of about 25 to about 50 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of at least 25 mg/mL. In some embodiments, the composition comprises gel-forming associated proteins at a concentration of no more than 25 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises fibrinogen at a concentration of at least 20 μg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 20 to about 100 μg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 100 to about 500 μg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 500 to about 1,000 μg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 1 to about 5 mg/mL. In some embodiments, the composition comprises fibrinogen at a concentration of about 5 to about 10 mg/mL. In some embodiments, the composition comprises fibrinogen at a concentration no higher than 10 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprise stabilizing proteins. Stabilizing proteins help stabilize proteins and prevent aggregation. A stabilizing protein can include, but is not limited to, albumin. In some embodiments, a stabilizing protein is albumin. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 0.1 ng/mL to about 500 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 0.1 to about 500 ng/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 500 to about 1 pg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 1 to about 500 μg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 1 to about 500 μg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 1 to about 50 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 50 to about 100 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 100 to about 250 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of about 250 to about 500 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of at least 500 mg/mL. In some embodiments, the composition comprises stabilizing proteins at a concentration of no more than 500 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprise immunoglobulins. Immunoglobulins are antibodies that recognize and bind antigens. In some embodiments, immunoglobulins are selected from immunoglobulin M (IgM), immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin D (IgD). In some embodiments, the immunoglobulin is IgM. In some embodiments the immunoglobulin is IgG. In some embodiments, the immunoglobulin is IgA. In some embodiments, the immunoglobulin IgE. In some embodiments, the immunoglobulin is IgD. In some embodiments, the composition comprises immunoglobulins at a concentration of about 50 ng/mL to about 2 mg/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 50 to about 250 ng/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 250 to about 500 ng/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 500 to about 1,000 ng/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 1 to about 100 μg/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 250 to about 500 μg/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 500 to about 1000 μg/mL. In some embodiments, the composition comprises immunoglobulins at a concentration of about 1 to about 2 mg/mL. In some embodiments, the composition comprises immunoglobulins at a concentration no higher than 2 mg/mL.

In some embodiments, the allogeneic human plasma and platelet suspension derived fraction comprises stabilizing lipids. Stabilizing lipids help stabilize the platelet and plasma proteins. In some embodiments, the stabilizing lipid found in platelet-rich plasma is selected from cholesterol and triglycerides. In some embodiments, the stabilizing lipid is cholesterol. In some embodiments, the stabilizing lipids are triglycerides. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 0.1 ng/mL to about 100 mg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 0.1 to about 500 ng/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 500 to about 1 μg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 1 to about 500 μg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 1 to about 500 μg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 1 to about 50 mg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of about 50 to about 100 mg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of at least 100 mg/mL. In some embodiments, the composition comprises stabilizing lipids at a concentration of no more than 100 mg/mL.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the composition comprises greater than 40% w/w human serum albumin (HSA). In some embodiments, the composition comprises no more than 40% w/w HSA. In some embodiments, the composition comprises 40% w/w HSA. In some embodiments, the composition comprises about 60% to about 70% w/w albumin. In some embodiments, the composition comprises 60-70% w/w albumin. In some embodiments, the composition comprises 60-70% w/w HSA.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the composition comprises greater than 20% w/w immunoglobulins. In some embodiments, the composition comprises no more than 20% w/w immunoglobulins. In some embodiments, the composition comprises 20% w/w immunoglobulins. In some embodiments, the composition comprises about 10% to about 20% w/w immunoglobulin. In some embodiments, the composition comprises 10-20% w/w immunoglobulins.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the composition comprises greater than 200 μg/mL A2M. In some embodiments, the composition comprises no more than 200 μg/mL A2M. In some embodiments, the composition comprises 200 μg/mL A2M.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the composition comprises about 20 μg/mL to about 10 mg/mL fibrinogen. In some embodiments, the composition comprises 10 μg/mL to about 2 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 10 mg/mL fibrinogen. In some embodiments, the composition comprises no less than 10 μg/mL fibrinogen. In some embodiments, the composition comprises no more than 10 mg/mL fibrinogen. In some embodiments, the composition comprises at least 10 mg/mL fibrinogen. In some embodiments, the composition comprises at least 20 μg/mL fibrinogen. In some embodiments, the composition comprises no more than 20 μg/mL fibrinogen. In some embodiments, the composition comprises at least 2 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 2 mg/mL fibrinogen. In some embodiments, the composition comprises 0.25-5.0 mg/mL fibrinogen. In some embodiments, the composition comprises 0.25-0.5 mg/mL fibrinogen. In some embodiments, the composition comprises 0.5-1.0 mg/mL fibrinogen. In some embodiments, the composition comprises 1-2 mg/mL fibrinogen. In some embodiments, the composition comprises 2-5 mg/mL fibrinogen. In some embodiments, the composition comprises about 0.25 to about 5.0 mg/mL fibrinogen. In some embodiments, the composition comprises about 0.25 to about 0.5 mg/mL fibrinogen. In some embodiments, the composition comprises about 0.5 to about 1.0 mg/mL fibrinogen. In some embodiments, the composition comprises about 1 to about 2 mg/mL fibrinogen. In some embodiments, the composition comprises about 2 to about 5 mg/mL fibrinogen.

In some embodiments, the allogeneic human plasma and platelet derived product comprises platelet proteins. In some embodiments, the platelet proteins are selected from Adiponectin/Acrp30, IFN-gamma, CCL2/MCP-1, Angiogenin, IGFBP-2, CCL7/MCP-3, Angiopoietin-1, IGFBP-3 M-CSF, Angiopoietin-2, IL-1 alpha/IL-1F1, MIF, Apolipoprotein A1, IL-1 beta/IL-1F2, BAFF/BLyS/TNFSF13B, IL-1ra/IL-1F3, CCL3/CCL4, BDNF, IL-2, CCL20/MIP-3 alpha, CD14, IL-3, CCL19/MIP-3 beta, CD30, IL-4, MMP-9, CD31/PECAM-1, IL-5, Myeloperoxidase, CD40 Ligand/TNFSF5, IL-6, Osteopontin (OPN), Chitinase 3-like, IL-8, PDGF-AA, Complement Component C5/C5a, IL-10, PDGF-AB/BB, Complement Factor D, IL-11, Pentraxin 3/TSF-14, C-Reactive Protein/CRP, IL-12 p70, CXCL4/PF4, Cripto-1, IL-13, RAGE, Cystatin C, IL-15, CCL5/RANTES, Dkk-1, IL-16, RBP4, DPPIV/CD26, IL-17A, Relaxin-2, EGF, IL-18 BPa, Resistin, CXCL5/ENA-78, IL-19, CXCL12/SDF-1 alpha, Endoglin/CD105, IL-22, Serpin E1/PAI-1, EMMPRIN, SHBG, Fas Ligand, ST2/IL1, R4, FGF basic, IL-27, CCL17/TARC, KGF/FGF-7, IL-31, TFF3, FGF-19, IL-32 alpha/beta/gamma, TfR, Flt-3 Ligand, TGF-alpha, G-CSF, Thrombospondin-1, GDF-15, CXCL10/IP-10, TIM-1, GM-CSF, CXCL11/I-TAC, CXCL1/GRO alpha, Kallikrein 3/PSA, uPAR, Growth Hormone (GH), Leptin, VCAM-1, HGF, VEGF, ICAM-1/CD54, Lipocalin-2/NGAL, Vitamin D BP, and any combination thereof. In some embodiments, the platelet proteins are Adiponectin/Acrp30, IFN-gamma, CCL2/MCP-1, Angiogenin, IGFBP-2, CCL7/MCP-3, Angiopoietin-1, IGFBP-3 M-CSF, Angiopoietin-2, IL-1 alpha/IL-1F1, MIF, Apolipoprotein A1, IL-1 beta/IL-1F2, BAFF/BLyS/TNFSF13B, IL-1ra/IL-1F3, CCL3/CCL4, BDNF, IL-2, CCL20/MIP-3 alpha, CD14, IL-3, CCL19/MIP-3 beta, CD30, IL-4, MMP-9, CD31/PECAM-1, IL-5, Myeloperoxidase, CD40 Ligand/TNFSF5, IL-6, Osteopontin (OPN), Chitinase 3-like, IL-8, PDGF-AA, Complement Component C5/C5a, IL-10, PDGF-AB/BB, Complement Factor D, IL-11, Pentraxin 3/TSF-14, C-Reactive Protein/CRP, IL-12 p70, CXCL4/PF4, Cripto-1, IL-13, RAGE, Cystatin C, IL-15, CCL5/RANTES, Dkk-1, IL-16, RBP4, DPPIV/CD26, IL-17A, Relaxin-2, EGF, IL-18 BPa, Resistin, CXCL5/ENA-78, IL-19, CXCL12/SDF-1 alpha, Endoglin/CD105, IL-22, Serpin E1/PAI-1, EMMPRIN, SHBG, Fas Ligand, ST2/IL1, R4, FGF basic, IL-27, CCL17/TARC, KGF/FGF-7, IL-31, TFF3, FGF-19, IL-32 alpha/beta/gamma, TfR, Flt-3 Ligand, TGF-alpha, G-CSF, Thrombospondin-1, GDF-15, CXCL10/IP-10, TIM-1, GM-CSF, CXCL11/I-TAC, CXCL1/GRO alpha, Kallikrein 3/PSA, uPAR, Growth Hormone (GH), Leptin, VCAM-1, HGF, VEGF, ICAM-1/CD54, Lipocalin-2/NGAL, and Vitamin D BP.

In some embodiments, the platelet proteins of the composition comprising plasma and platelet derived proteins comprises comprise growth factors. Growth factors promote cell growth and division. In some embodiments, the composition comprising plasma and platelet derived proteins comprises growth factors selected from, platelet-derived growth factor (PDGF (AB, AA, BB)), transcription growth factor-β1 (TGFβ1), transcription growth factor-β2 (TGFβ2), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF), hepatocyte growth factor (HGF), basic-fibroblast growth factor (b-FGF), insulin-like growth factor 1 (IGF-1), glia maturation factor-β (GMFB), and any combination thereof. In some embodiments, the composition comprising plasma and platelet derived proteins comprises growth factors PDGF-AA, PDGF-BB, PDGF-AB, TGFβ, VEGF, EGF, BNDF, HGF, b-FGF, IGF-1, and GMFB. PDGF promotes cell growth and generation, repair of blood vessels and collagen production. VEGF promotes growth and generation of vascular endothelial cells. FGF promotes tissue repair, cell growth, collagen production and hyaluronic acid production. EGF promotes epithelial cell growth, angiogenesis and wound healing. TGF, especially TGF-β, promotes growth and neogenesis of epithelial cells and wound healing. In some embodiments, the composition comprising plasma and platelet derived proteins comprises growth factors at a concentration of about 0.1 to about 100 pg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 100 to about 500 pg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 0.1 to 100 ng/mL. In some embodiments, the composition comprises growth factors at a concentration of about 100 to about 500 ng/mL. In some embodiments the composition comprises growth factors at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 1 to about 2 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 2 to about 3 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 3 to about 4 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of about 4 to about 5 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of at least 5 mg/mL. In some embodiments, the composition comprises growth factors at a concentration of more than 5 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 5 to about 200 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 10 to about 20 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 20 to about 40 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 40 to about 80 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 80 to about 160 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 5 to about 200 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 10 to about 20 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 20 to about 40 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 40 to about 80 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises PDGF-AB at a concentration of about 80 to about 160 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 50 to about 1000 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 50 to about 150 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 150 to about 300 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 300 to about 500 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 500 to about 1000 ng/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 50 to about 1000 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 50 to about 150 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 150 to about 300 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 300 to about 500 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises TGFβ at a concentration of about 500 to about 100 ng/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 50 to about 1500 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 50 to about 200 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 200 to about 400 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 400 to about 800 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 800 to about 1500 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 50 to about 1500 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 50 to about 200 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 200 to about 400 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 400 to about 800 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises VEGF at a concentration of about 800 to about 1500 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 100 to about 5000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 100 to about 1000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 1000 to about 2000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 2000 to about 4000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 4000 to about 6000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 100 to about 5000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 100 to about 1000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 1000 to about 2000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 2000 to about 4000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises EGF at a concentration of about 4000 to about 6000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 100 to about 3000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 100 to about 300 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 300 to about 600 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 600 to about 1200 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 1200 to about 3000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 100 to about 3000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 100 to about 300 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 300 to about 600 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 600 to about 1200 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises FGF at a concentration of about 1200 to about 3000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 25 to about 2500 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 25 to about 150 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 150 to about 300 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 300 to about 1000 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 1000 to about 2500 pg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 25 to about 2500 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 25 to about 150 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 150 to about 300 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 300 to about 1000 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%. In some embodiments, the composition comprising plasma and platelet derived proteins comprises HGF at a concentration of about 1000 to about 2500 pg/mL, +/−5%, 10%, 15%, 20%, 25%, or 30%.

In some embodiments, the composition comprises anti-inflammatory proteins. Anti-inflammatory proteins are derived from the plasma and/or platelets. In some embodiments, platelet proteins of the composition comprising plasma and platelet derived proteins comprise anti-inflammatory proteins. Anti-inflammatory proteins regulate the immune and inflammatory responses and reduce inflammation. In some embodiments, the composition comprising plasma and platelet derived proteins comprises anti-inflammatory proteins selected from interleukins (IL-1) and receptor antagonist protein (IRAP), interleukin 10 (IL-10), tissue inhibitor of metalloproteinase 1 (TIMP-1), and any combination thereof. In some embodiments, the composition comprising plasma and platelet derived proteins comprises anti-inflammatory proteins IL-1, IRAP, IL-10, and TIMP-1. In some embodiments, the composition comprising plasma and platelet derived proteins comprises anti-inflammatory proteins at a concentration of about 0.1 to about 5 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 0.1 to about 100 pg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 100 to about 500 pg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 0.1 to 100 ng/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 100 to about 500 ng/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 1 to about 2 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 2 to about 3 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 3 to about 4 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of about 4 to about 5 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of at least 5 mg/mL. In some embodiments, the composition comprises anti-inflammatory proteins at a concentration of no more than 5 mg/mL.

In some embodiments, the composition comprises anti-oxidant proteins. Anti-oxidant proteins are derived from the plasma and/or platelets. In some embodiments, platelet proteins of the composition comprising plasma and platelet derived proteins comprise anti-oxidant proteins. Anti-oxidant proteins help prevent radical oxidation from damaging cells. In some embodiments, the composition comprising plasma and platelet derived proteins comprises anti-oxidant proteins selected from, glutathione S-transferase (GST), glutathione peroxidase-1 (GPx-1), catalase, and any combination thereof. In some embodiments, platelet proteins of the composition comprising plasma and platelet derived proteins comprise anti-oxidant proteins GST, GPx-1, and catalase. In some embodiments, the composition comprising plasma and platelet derived proteins comprises anti-oxidant proteins at a concentration of about 0.1 to about 10 μg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 10 to about 100 μg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 100 to about 500 pg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 500 to about 1,000 pg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 1 to about 500 ng/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 500 to about 1,000 ng/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 0.1 to about 5 mg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 0.1 to about 10 pg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 10 to about 100 pg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 100 to about 500 pg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 0.5 to about 1 mg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of about 1 to about 5 mg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of at least 5 mg/mL. In some embodiments, the composition comprises anti-oxidant proteins at a concentration of no more than 5 mg/mL.

In some embodiments, the composition comprises human plasma and platelet derived proteins comprising IFNγ, IL-5, IL-1β, IL-6, IL-1RA, IL-10, IL-13, TNFα, IL-8, IL-12p40, MCP-1, and any combination thereof. In some embodiments, the composition comprises IFN at a concentration of about 0.1 to about 0.5 pg/mL. In some embodiments, the composition comprises IL-5 at a concentration of about 0.5 to about 2.0 pg/mL. In some embodiments, the composition comprises IL-1β at a concentration of about 1.0 to about 4.0 pg/mL. In some embodiments, the composition comprises IL-6 at a concentration of about 1.0 to about 5.0 pg/mL. In some embodiments, the composition comprises IL-1Ra at a concentration of about 2.0 to about 7.0 pg/mL. In some embodiments, the composition comprises IL-1β at a composition of about 2.0 to about 10.0 pg/mL. In some embodiments, the composition comprises IL-13 at a concentration of about 1.0 to about 10.0 pg/mL. In some embodiments, the composition comprises TNFα at a concentration of about 1.0 to about 5.0 pg/mL. In some embodiments, the composition comprises IL-8 at a concentration of about 20 to about 50 pg/mL. In some embodiments, the composition comprises IL-12p40 at a concentration of about 50 to about 80 pg/mL. In some embodiments, the composition comprises MCP-1 at a concentration of about 200 to about 300 pg/mL.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet proteins are selected from, platelet factor 4 (PF4), platelet-derived growth factor (PDGF (AB, AA, BB)), transcription growth factor-β 1 (TGFβ1), transcription growth factor-β 2 (TGFβ2), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF), hepatocyte growth factor (HGF), basic-fibroblast growth factor (b-FGF), insulin-like growth factor 1 (IGF-1), glia maturation factor-β (GMFB), cluster of differentiation 31 (CD31). In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet proteins are selected from, platelet factor 4 (PF4), platelet-derived growth factor (PDGF (AB, AA, BB)), transcription growth factor-β 1 (TGFβ1), transcription growth factor-β 2 (TGFβ2), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF), hepatocyte growth factor (HGF), fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1), glia maturation factor-β (GMFB), cluster of differentiation 31 (CD31). In some embodiments, the platelet proteins are PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, BDNF, HFG, b-FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins are PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, HFG, FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least PDGF-AB. In some embodiments, the platelet proteins comprise at least two of PF4, PDGF (AB, AA, BB)), TGFβ 1, TGFβ2, VEGF, EGF, BDNF, HFG, FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least three of PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, BDNF, HFG, FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least four of PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, BDNF, HFG, FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least two of PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, HFG, FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least three of PF4, PDGF (AB, AA, BB)), TGFβ 1, TGFβ2, VEGF, EGF, HFG, b-FGF, IGF-1, GMFB, and CD31. In some embodiments, the platelet proteins comprise at least four of PF4, PDGF (AB, AA, BB)), TGFβ1, TGFβ2, VEGF, EGF, HFG, FGF, IGF-1, GMFB, and CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises PF4. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises PDGF-AA. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises PDGF-BB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises TGFβ1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises TGFβ2. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises VEGF In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises EGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises BDNF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises HGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises b-FGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises IGF-1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises GMFB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises at least 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises no more than 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises between about 50 and 1,000 pg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises at least 50 pg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises no more than 50 pg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises at least 1,000 pg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises no more than 1,000 pg/mL PDGF-AB.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises no more than 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises about 5 ng/mL to about 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises about 10 ng/mL to about 20 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises about 20 ng/mL to about 40 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises about 40 ng/mL to about 80 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises about 80 ng/mL to about 160 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises no more than 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 5 ng/mL to 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 10 ng/mL to 20 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 20 ng/mL to 40 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 40 ng/mL to 80 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the platelet protein comprises 80 ng/mL to 160 ng/mL PDGF-AB.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the composition comprises greater than 40% w/w human serum albumin (HSA). In some embodiments, the composition comprises no more than 40% w/w HSA. In some embodiments, the composition comprises 40% w/w HSA. In some embodiments, the composition comprises about 60% to about 70% w/w HSA.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the composition comprises greater than 40% w/w human serum albumin (HSA). In some embodiments, the composition comprises no more than 40% w/w HSA. In some embodiments, the composition comprises 40% w/w HSA. In some embodiments, the composition comprises about 60% to about 70% w/w HSA.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the composition comprises greater than 20% w/w immunoglobulins. In some embodiments, the composition comprises no more than 20% w/w immunoglobulins. In some embodiments, the composition comprises 20% w/w immunoglobulins. In some embodiments, the composition comprises about 10% to about 20% w/w immunoglobulins.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the composition comprises greater than 20% w/w immunoglobulins. In some embodiments, the composition comprises no more than 20% w/w immunoglobulins. In some embodiments, the composition comprises 20% w/w immunoglobulins. In some embodiments, the composition comprises about 10% to about 20% w/w immunoglobulins.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the composition comprises greater than 200 μg/mL A2M. In some embodiments, the composition comprises no more than 200 μg/mL A2M. In some embodiments, the composition comprises 200 μg/mL A2M.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the composition comprises about 20 μg/mL to about 10 mg/mL fibrinogen. In some embodiments, the composition comprises 10 μg/mL to about 2 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 10 mg/mL fibrinogen. In some embodiments, the composition comprises no less than 10 μg/mL fibrinogen. In some embodiments, the composition comprises no more than 10 mg/mL fibrinogen. In some embodiments, the composition comprises at least 10 mg/mL fibrinogen. In some embodiments, the composition comprises at least 20 μg/mL fibrinogen. In some embodiments, the composition comprises no more than 20 μg/mL fibrinogen. In some embodiments, the composition comprises about 1 mg/mL to about 5 mg/mL fibrinogen. In some embodiments, the composition comprises at least 2 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 2 mg/mL fibrinogen.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the composition comprises about 0.25 mg/mL to about 5 mg/mL fibrinogen. In some embodiments, the composition comprises about 0.25 to about 0.5 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 5 mg/mL fibrinogen. In some embodiments, the composition comprises at least 1 mg/mL fibrinogen. In some embodiments, the composition comprises about 1 mg/mL to about 5 mg/mL fibrinogen. In some embodiments, the composition comprises at least 2 mg/mL fibrinogen. In some embodiments, the composition comprises no more than 2 mg/mL fibrinogen. In some embodiments, the composition comprises about 1 mg/mL to about 2 mg/mL fibrinogen. In some embodiments, the composition comprises about 2 mg/mL to about 5 mg/mL fibrinogen. In some embodiments, the composition comprises about 0.5 mg/mL to about 1 mg/mL fibrinogen.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and a combination thereof. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, alpha-2-macroglobulin (A2M), and immunoglobulins, and wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, HGF, b-FGF, IGF-1, GMFB, CD31, and a combination thereof. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, alpha-2-macroglobulin (A2M), and immunoglobulins, and wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, HGF, b-FGF, IGF-1, GMFB, and CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are at least one of albumin, fibrinogen, alpha-2-macroglobulin (A2M), and immunoglobulins, and wherein the platelet proteins are at least one of PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, HGF, FGF, IGF-1, GMFB, CD31, and a combination thereof. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, alpha-2-macroglobulin (A2M), and immunoglobulins, and wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, HGF, FGF, IGF-1, GMFB, and CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PF4t. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-AA. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-BB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-AB. In some embodiments, the composition comprises human plasma proteins and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises TGF 1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises TGFβ2. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises VEGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises EGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises BDNF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises HGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises b-FGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises IGF-1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises GMFB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises at least 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises no more than 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises 20 μg/mL PDGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises between about 50 and 1,000 μg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises at least 50 μg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises no more than 50 μg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises at least 1,000 μg/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, alpha-2-macroglobulin (A2M), immunoglobulins, and a combination thereof, and wherein the platelet protein comprises no more than 1,000 μg/mL PDGF-AB.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet proteins are selected from PDGF (PDGF-AB, PDGF-AA, and/or PDGF-BB), TGFβ (TGFβ1 and/or TGFβ2), VEGF, EGF, FGF, HGF, and a combination thereof. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, and wherein the platelet proteins are PDGF (PDGF-AB, PDGF-AA, and/or PDGF-BB), TGFβ (TGFβ1 and/or TGFβ2), VEGF, EGF, FGF, and HGF.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are at least one of albumin, fibrinogen, and immunoglobulins, and wherein the platelet proteins are at least one of PDGF (PDGF-AB, PDGF-AA, and/or PDGF-BB), TGFβ (TGFβ 1 and/or TGFβ2), VEGF, EGF, FGF, HGF, and a combination thereof.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PF4t. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-AA. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-BB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises PDGF-AB. In some embodiments, the composition comprises human plasma proteins and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises TGFβ1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises TGFβ2. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises VEGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises EGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises BDNF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises HGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises b-FGF. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises IGF-1. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises GMFB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises CD31.

In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises about 5 to about 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises at least 5 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises no more than 200 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises about 10 to about 20 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises about 20 to about 40 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises about 40 to about 80 ng/mL PDGF-AB. In some embodiments, the composition comprises human plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and a combination thereof, and wherein the platelet protein comprises about 80 to about 60 ng/mL PDGF-AB.

In some embodiments, the allogenic human plasma and platelet derived product comprises a composition with reduced concentrations of plasma proteins. In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition with a reduced concentration of albumin. In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition substantially of platelet proteins.

High Concentration Allogeneic Human Plasma and Platelet Derived Product

In some embodiments, the composition of the disclosure provides a high concentration allogeneic human plasma and platelet derived product. In some embodiments, the disclosure provides a composition comprising a high concentration of human plasma and platelet derived proteins. In some embodiments, the disclosure provides a composition comprising a high concentration of human plasma and platelet derived proteins, wherein the composition comprises a total protein concentration of greater than 50 mg/mL. In some embodiments, the total protein concentration is greater than 50 mg/mL and less than 500 mg/mL. In some embodiments, the total protein concentration is greater than 75 mg/mL and less than 500 mg/mL. In some embodiments, the total protein concentration is at least 75 mg/mL and less than 500 mg/mL. In some embodiments, the total protein concentration is at least 100 mg/mL and less than 500 mg/mL. In some embodiments, the total protein concentration is about 50 mg/mL to about 500 mg/mL. In some embodiments, the total protein concentration is about 75 mg/mL to about 450 mg/mL. In some embodiments, the total protein concentration is about 75 mg/mL to about 300 mg/mL. In some embodiments, the total protein concentration is about 100 mg/mL to about 300 mg/mL. In some embodiments, the total protein concentration is about 150 mg/mL to about 300 mg/mL. In some embodiments, the total protein concentration is about 100 mg/mL to about 250 mg/mL. In some embodiments, the total protein concentration is about 50 to about 60 mg/mL. In some embodiments, the total protein concentration is about 60 to about 70 mg/mL. In some embodiments, the total protein concentration is about 70 to about 80 mg/mL. In some embodiments, the total protein concentration is about 80 to about 90 mg/mL. In some embodiments, the total protein concentration is about 90 to about 100 mg/mL. In some embodiments, the total protein concentration is at least 100 mg/mL. In some embodiments, the total protein concentration is about 100 to about 200 mg/mL. In some embodiments, the total protein concentration is at least 200 mg/mL. In some embodiments, the total protein concentration is no more than 250 mg/mL.

In some embodiments, the disclosure provides a composition comprising human plasma and platelet derived proteins, wherein the composition comprises a total protein concentration of at least 20 mg/mL. In some embodiments, the total protein concentration is about 20 mg/mL to about 50 mg/mL. In some embodiments, the total protein concentration is about 20 mg/mL to about 500 mg/mL. In some embodiments, the total protein concentration is about 50 mg/mL to about 80 mg/mL. In some embodiments, the total protein concentration is about 80 mg/mL to about 160 mg/mL. In some embodiments, the total protein concentration is about 160 mg/mL to about 320 mg/mL. In some embodiments, the total protein concentration is about 30 mg/mL+/−5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the total protein concentration is about 30 mg/mL+/−25%. In some embodiments, the total protein concentration is about 60 mg/mL+/−5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the total protein concentration is about 60 mg/mL+/−25%. In some embodiments, the total protein concentration is about 120 mg/mL+/−5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the total protein concentration is about 120 mg/mL+/−25%. In some embodiments, the total protein concentration is about 240 mg/mL+/−5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%. In some embodiments, the total protein concentration is about 240 mg/mL+/−25%.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 100 to about 300 mg/mL.

Total protein concentration can be evaluated with any standard technique known to those with ordinary skill in the art. In some embodiments, a bicinchoninic acid assay (BCA) is used to evaluate total protein concentration. The BCA (Bicinchoninic Acid) assay, a colorimetric method of detection based on complexation of proteins with copper and BCA. The principle of the bicinchoninic acid (BCA) assay relies on the formation of a Cu2+-protein complex under alkaline conditions, followed by reduction of the Cu2+ to Cu+. The amount of reduction is proportional to the protein present. BCA forms a purple-blue complex with Cu+ in alkaline environments, thus providing a basis to monitor the reduction of alkaline Cu2+ by proteins at absorbance maximum 562 nm. In some embodiments, a Bradford assay is used to evaluate total protein concentration. In some embodiments, UV-vis/A 280 is used to evaluate total protein concentration. In some embodiments, a Lowry assay is used to evaluate total protein concentration.

Viscosity

In some embodiments, the composition comprises a viscosity that allows for localization and maintenance of the platelet and plasma proteins at the site of injection. Viscosity is a measure of the resistance of the gel to being deformed by either shear stress or tensile stress. Viscosity can be measured using any method known in the art. Suitable methods include, but are not limited to, using a viscometer or a rheometer.

In some embodiments, viscosity of the of the composition is determined at room temperature and quantified as centipoise (cP). In some embodiments, the viscosity is 1 to 50 cP. In some embodiments, the viscosity is 1 to 40 cP. In some embodiments, the viscosity is less than 40 cP. In some embodiments, the viscosity is 5 to 40 cP. In some embodiments, the viscosity is 10 to 30 cP. In some embodiments, the viscosity is 10 to 25 cP. In some embodiments, the viscosity is 10 to 15 cP. In some embodiments, the viscosity is at least 5 cP and no greater than 25 cP. In some embodiments, the viscosity is less than 50 cP. In some embodiments, the viscosity is about 1 to 2 cP. In some embodiments, the viscosity is about 3 to about 5 cP. In some embodiments, the viscosity is about 5 to about 10 cP. In some embodiments, the viscosity is about 10 to about 15 cP. In some embodiments, the viscosity is about 10 to about 20 cP. In some embodiments, the viscosity is about 20 to about 50 cP. In some embodiments, the viscosity is about 2 cP. In some embodiments, the viscosity is about 3 cP. In some embodiments, the viscosity is about 10 cP. In some embodiments, the viscosity is about 12 cP. In some embodiments, the viscosity is about 15 cP. In some embodiments, the viscosity is 20 cP. In some embodiments, the viscosity is at least 10 cP. In some embodiments, the viscosity is at least 15 cP. In some embodiments, the viscosity is no greater than 15 cP. In some embodiments, the viscosity is less than 25 cP, less than 20 cP, less than 15 cP, or less than 10 cP.

In some embodiments, viscosity of a high concentration composition comprising plasma and platelet derived proteins is reduced. In some embodiments, viscosity is reduced by dilution of the high concentration composition. In some embodiments, viscosity is reduced by using a viscosity modifier. In some embodiments, a viscosity modifier is arginine, a salt, or a hydrophobicity binder (e.g., tryptophan).

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and immunoglobulins, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is no more than 50 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising plasma and platelet derived proteins, wherein the plasma proteins are albumin and fibrinogen, the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the viscosity is about 10 to about 25 cP.

pH and Osmolality

In some embodiments, the composition comprising an allogeneic human plasma and platelet derived product has a pH of about 4.5 to about 8.5. In some embodiments the pH is about 5.0 to about 8.5. In some embodiments the pH is about 5.5 to about 8.5. In some embodiments the pH is about 6.0 to about 8.5. In some embodiments the pH is about 6.5 to about 8.5. In some embodiments the pH is about 7.0 to about 8.5. In some embodiments the pH is about 7.5 to about 8.5. In some embodiments, the pH is about 4.5 to about 8.0. In some embodiments, the pH is about 4.5 to about 7.5. In some embodiments, the pH is about 4.5 to about 7.0. In some embodiments, the pH is about 4.5 to about 6.5. In some embodiments, the pH is about 4.5 to about 6.0. In some embodiments, the pH is about 4.5 to about 5.5.

In some embodiments, the composition comprising an allogeneic human plasma and platelet derived product has an osmolality of about 200 to about 500 mOsmo/kg. In some embodiments, osmolality is measured via a freezing point osmometer. In some embodiments, an osmolality of about 200 to about 500 mOsmo/kg allows for proteins to remain stable. In some embodiments, an osmolality of about 200 to about 500 mOsmo/kg allows for injection into a subject.

Characterization of Composition

In some embodiments, the presence of platelet proteins and/or plasma proteins is determined by detecting protein levels. In some embodiments, the concentration of platelet and/or plasma proteins is determined by quantifying protein levels. In some embodiments, the total protein concentration of the allogeneic human plasma and platelet e derived product is determined using methods for detecting and quantifying proteins. Methods for detecting and quantifying proteins are known in the art and described herein, for example, western blot, CE-SDS, SDS-PAGE, immunosorbent assays, BCA, etc. In some embodiments, the presence of platelet proteins and/or plasma proteins is determined by SDS-PAGE. Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used to obtain high resolution separation of complex mixtures of proteins that comprise allogenic human platelet concentrate. This method allows protein separation by mass. Allogenic human platelet concentrate samples are diluted in a sample buffer containing SDS which denatures protein-protein interactions and mask the proteins' intrinsic charge making them similar charge-to-mass ratios. When a current is applied, all SDS-bound proteins will migrate through a gel towards the positively charged electrode. The gel is stained using an intercalating dye, visualized, and analyzed using densitometry for gross evaluation of protein composition.

In some embodiments, the presence of platelet proteins and/or plasma proteins is determined by capillary electrophoreses sodium dodecyl sulfate (CE-SDS). Protein analysis by CE-SDS relies on separation of SDS-bound protein variants by a sieving matrix (i.e. polymer) in a constant electric field. This method yields higher resolution compared to SDS-PAGE and allows for identification and purity analysis of proteins.

In some embodiments, the presence or quantity of platelet proteins and/or plasma proteins is determined by ELISA. In some embodiments, the presence or quantity of platelet proteins and/or plasma proteins is determined by quantitative sandwich enzyme immunoassay. In a quantitative sandwich enzyme immunoassay, a first antibody is coated on the surface of the multi-well plate and used as a capture antibody to facilitate the immobilization of the antigen. A second antibody can be conjugated to facilitate the detection of the antigen.

In some embodiments, the presence or quantity of platelet proteins and/or plasma proteins is determined by Meso Scale Discovery (MSD) assays. MSD relies on the same principle as ELISA but requires electrochemiluminescent signals as a detection method.

In some embodiments, the presence and/or quantity of cytokines is determined with a cytokine panel. In some embodiments, the cytokine panel is evaluated via mass spectrometry. In some embodiments, the cytokine panel is evaluated via an immunosorbent assay (e.g., ELISA, cytokine arrays). A human cytokine array is a rapid, sensitive, and economic tool to simultaneously detect multiple cytokines. Carefully selected capture antibodies are spotted in duplicate on nitrocellulose membranes. The allogeneic human platelet concentrate/antibody mixture is first diluted and incubated with the Human Cytokine Array membrane. Any cytokine/detection antibody complex present is bound by its cognate immobilized capture antibody on the membrane. Following a wash to remove unbound material, Streptavidin-HRP and chemiluminescent detection reagents are added sequentially. Light is produced at each spot in proportion to the amount of cytokine bound.

In some embodiments, the presence of A2M is determined with an enzyme linked immunosorbent assay (ELISA). In some embodiments, A2M content is determined using a commercially available sandwich ELISA. In this assay, the antibody specific for A2M is bound to the solid phase or support. A composition of interest is contacted with the solid phase or support to extract the antigen (A2M) from the sample by formation of a binary solid phase antibody:antigen complex. After a suitable incubation period, the solid support is washed to remove any unbound substances. An enzyme-linked biotinylated-polyclonal antibody specific for human A2M is then added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution containing streptavidin-HRP is added to the wells and color develops in proportion to the amount of A2M bound in the initial step. The color development is stopped, and the intensity of the color is measured. Total A2M is determined via absorption and extrapolated from an A2M standard curve.

In some embodiments, the function of platelet proteins is determined by ELISA. In some embodiments, the function of PF4 is evaluated with a AlphaLISA kit by Revvity (Cat. No. AL398HV). In some embodiments, the function of PDGF is evaluated with a Human Platelet-Derived Growth Factor Receptor α and β (PDGFRα/β) kit by INDIGO Biosciences (Cat. No. IB23001). In some embodiments, the quantity of PDGF is determined by ELISA. In some embodiments the quantity of PDGF is evaluated with a Human Platelet-Derived Growth Factor Receptor α and β (PDGFRα/β) kit by INDIGO Biosciences (Cat. No. IB23001).

In some embodiments, the function of TFBβ is evaluated with a Human TGFβR Reporter Assay Kit by INDIGO Biosciences (Cat. NO. IB12001). In some embodiments, the quantity of TFBβ is evaluated with a Human TGFβR Reporter Assay Kit by INDIGO Biosciences (Cat. NO. IB12001). In some embodiments, the function of VEGF is evaluated with bioluminescence with a VEGF Bioassay kit by Promega (Cat. No. GA2001). In some embodiments, the quantity of VEGF is evaluated with bioluminescence with a VEGF Bioassay kit by Promega (Cat. No. GA2001). In some embodiments, the function of EGF is evaluated with a ELISA kit by Eagle Biosciences (Cat. No. EGF31-K01). In some embodiments, the quantity of EGF is evaluated with a ELISA kit by Eagle Biosciences (Cat. No. EGF31-K01). In some embodiments, the function of BDNF is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EH42RB). In some embodiments, the function of HGF is evaluated with an ELISA kit by Thermo Fisher (Cat. No. KAC2211). In some embodiments, the quantity of HGF is evaluated with an ELISA kit by Thermo Fisher (Cat. No. KAC2211). In some embodiments, the function of b-FGF is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EB2RB). In some embodiments, the quantity of b-FGF is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EB2RB). In some embodiments, the function of IGF-1 is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EH250RB). In some embodiments, the function of CD31 is evaluated with an ELISA kit by Thermo Fisher (Cat. No. BMS229). In some embodiments, the function of albumin is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EHALB). In some embodiments, the function of fibrinogen is evaluated with an ELISA kit by AbCam (Cat. No. ab241383). In some embodiments, the quantity of fibrinogen is evaluated with an ELISA kit by AbCam (Cat. No. ab241383). In some embodiments, the function of A2M is evaluated with an ELISA kit by Thermo Fisher (Cat. No. EH20RB). In some embodiments, the function of IgM is evaluated with an ELISA kit by Thermo Fisher (Cat. No. BMS2098). In some embodiments, the function of IgG is evaluated with an ELISA kit by Thermo Fisher (Cat. No. BMS2091). In some embodiments, the function of IgA is evaluated with an ELISA kit by Thermo Fisher (Cat. No. BMS2096). In some embodiments, the function of IgE is evaluated with an ELISA kit by Thermo Fisher (Cat. No. BMS2097).

In some embodiments, the function of platelet proteins is determined by a cellular assay. In some embodiments, the cellular assay is a reporter assay to quantify functional activity of a protein. For example, in some embodiments, a cellular assay comprises contacting cells having a luciferase reporter gene functionally linked to a promoter responsive to a protein of interest, wherein contacting the cells with the composition indicates whether the protein of interest is functioning in the composition. In some embodiments, the cellular assay comprises stimulating a cell line with an inducer of proinflammatory cytokines and contacting the cell line with the composition to determine whether proinflammatory cytokines are reduced. In some embodiments, the function of platelet proteins. An exemplary functional assay is described by Singh, U. et al. (Clin. Chem. 2005 Dec., Vol. 51(12)2252-6) (hereby incorporated by reference in its entirety).

In some embodiments, the immunogenicity of the composition is determined. In some embodiments, immunogenicity is determined by contacting donor peripheral blood mononuclear cells (PBMCs) with the composition and quantifying levels of CD134 and/or CD137 on CD4+ T cells, as increased levels of these markers on CD4+ T cells indicates immunogenic risk of the composition. An exemplary assay for assessing immunogenicity is described in Cohen, S. et al. (MABS, 2021, Vol. 13(1): e1898831 (hereby incorporated by reference in its entirety)).

In some embodiments, the impact of the composition on cell migration and/or cell proliferation is determined. In some embodiments, cell migration and/or cell proliferation is determined by an in vitro scratch assay. In brief, a “wound” is created in a cell monolayer and then contacted with a composition described herein. Cell migration to close the “wound” is determined by capturing images over time and comparing the images to quantity the migration rate of the cells. An exemplary scratch assay is described in Rodriguez, L. et al. (Methods Mol Biol. 2005, Vol. 294: 23-9 (hereby incorporated by reference in its entirety)).

Exemplary Compositions I

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, immunoglobulins, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, A2M, and any combination thereof, the platelet proteins are selected from PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, A2M, and immunoglobulins, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ 1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 1 to about 40 cP.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, CD31, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are albumin, fibrinogen, and A2M, the platelet proteins are PF4, PDGFAB, PDGFAA, PDGFBB, TGFβ1, TGFβ2, VEGF, EGF, BDNF, HGF, b-FGF, IGF-1, GMFB, and CD31, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is greater than 50 pg/mL and less than 1,000 pg/mL, the fibrinogen concentration is about 1-5 mg/mL, and the viscosity is about 10 to about 25 cP.

In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition summarized in Table 1.

In some embodiments, the allogeneic human Plasma and Platelet derived product comprises a composition summarized in Table 2.

In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition summarized in Table 3.

In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition summarized in Table 4.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, and PDGF at a concentration of about 20 μg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL and PDGF at a concentration of about 20 μg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of at least 50 mg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of at least 50 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of about 50 mg/mL to about 500 mg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of about 50 mg/mL to about 500 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of about 100 mg/mL to about 300 mg/mL. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a total protein concentration of about 100 mg/mL to about 300 mg/mL.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a viscosity of about 10 to about 25 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a viscosity of about 10 to about 25 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of at least 50 mg/mL, and a viscosity of about 10 to about 25 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of at least 50 mg/mL, and a viscosity of about 10 to about 25 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 50 mg/mL to about 500 mg/mL, and a viscosity of about 10 to about 25 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 50 mg/mL to about 500 mg/mL, and a viscosity of about 10 to about 25 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 100 mg/mL to about 300 mg/mL, and a viscosity of about 10 to about 25 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 100 mg/mL to about 300 mg/mL, and a viscosity of about 10 to about 25 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a viscosity of about 1 to about 40 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, and a viscosity of about 1 to about 40 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of at least 50 mg/mL, and a viscosity of about 1 to about 40 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of at least 50 mg/mL, and a viscosity of about 1 to about 40 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 50 mg/mL to about 500 mg/mL, and a viscosity of about 1 to about 40 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 50 mg/mL to about 500 mg/mL, and a viscosity of about 1 to about 40 cP.

In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 10 mg/mL, immunoglobulins at a concentration of about 20% w/w, α-2-macroglobulin (A2M) at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 μg/mL, a total protein concentration of about 100 mg/mL to about 300 mg/mL, and a viscosity of about 1 to about 40 cP. In some embodiments, the composition comprising plasma and platelet derived proteins comprises albumin at concentration of about 100 to 1,400 μg/mL, fibrinogen at a concentration of about 20 μg/mL to about 2 mg/mL, immunoglobulins at a concentration of about 20% w/w, A2M at a concentration of about 200 μg/mL, PDGF at a concentration of about 20 pg/mL, a total protein concentration of about 100 mg/mL to about 300 mg/mL, and a viscosity of about 1 to about 40 cP.

Exemplary Compositions II

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulin, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulin, and any combination thereof and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulin, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the platelet proteins are PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, and HGF, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is at least 50 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 50 to about 500 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, and the total protein concentration is about 100 to about 300 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is at least 50 mg/mL, and the fibrinogen concentration is about 1-5 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ 1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, and the fibrinogen concentration is about 1-5 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, and the fibrinogen concentration is about 1-5 mg/mL.

In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is at least 50 mg/mL, the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL, and the fibrinogen concentration is about 1-5 mg/mL In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 50 to about 500 mg/mL, the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL, and the fibrinogen concentration is about 1-5 mg/mL. In some embodiments, the disclosure provides a composition comprising a high concentration of plasma and platelet derived proteins, wherein the plasma proteins are selected from albumin, fibrinogen, immunoglobulins, and any combination thereof, the platelet proteins are selected from PDGF-AB, PDGF-AA, PDGF-AB, TGFβ1, TGFβ2, VEGF, EGF, FGF, HGF, and any combination thereof, the total protein concentration is about 100 to about 300 mg/mL, the PDGF-AB concentration is about 5 ng/mL to about 200 ng/mL, and the fibrinogen concentration is about 1-5 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, the fibrinogen concentration is 0.25-5.0 mg/mL, and the PDGF-AB concentration is 5-200 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, the fibrinogen concentration is 0.25-5.0 mg/mL, and the PDGF-AB concentration is 5-200 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, the fibrinogen concentration is 0.25-5.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is 5-200 ng/mL, the TGFβ concentration is 50-1000 ng/mL, the VEGF concentration is 50-1500 pg/mL, the EGF concentration is 100-5000 pg/mL, the FGF concentration is 100-3000 pg/mL, and the HGF concentration is 25-2500 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 20 mg/mL to about 50 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 20 mg/mL to about 50 mg/mL, the fibrinogen concentration is 0.25-0.5 mg/mL, and the PDGF-AB concentration is 10-20 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 30 mg/mL+/−25%, the fibrinogen concentration is 0.25-0.5 mg/mL, and the PDGF-AB concentration is 10-20 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 20 mg/mL to about 50 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 20 mg/mL to about 50 mg/mL, the fibrinogen concentration is 0.25-0.5 mg/mL, and the PDGF-AB concentration is 10-20 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 30 mg/mL+/−25%, the fibrinogen concentration is 0.25-0.5 mg/mL, and the PDGF-AB concentration is 10-20 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 20 mg/mL to about 50 mg/mL, the fibrinogen concentration is 0.25-0.5 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 10 to about 20 ng/mL, the TGF-β concentration is about 50 ng/mL to about 150 ng/mL, the VEGF concentration is about 50 pg/mL to about 200 pg/mL, the EGF concentration is about 100 pg/mL to about 1000 pg/mL, the FGF concentration is about 100 pg/mL to about 300 pg/mL, and the HGF concentration is about 25 pg/mL to about 150 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 30 mg/mL+/−25%, the fibrinogen concentration is 0.25-0.5 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 10 to about 20 ng/mL, the TGF-β concentration is about 50 ng/mL to about 150 ng/mL, the VEGF concentration is about 50 pg/mL to about 200 pg/mL, the EGF concentration is about 100 pg/mL to about 1000 pg/mL, the FGF concentration is about 100 pg/mL to about 300 pg/mL, and the HGF concentration is about 25 pg/mL to about 150 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 50 mg/mL to about 80 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 60 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 60 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 50 mg/mL to about 80 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 60 mg/mL+/−25%, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 60 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 50 mg/mL to about 80 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 50 mg/mL to about 80 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL+/−25%, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, and the PDGF-AB concentration is 20-40 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 50 mg/mL to about 80 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 20 to about 40 ng/mL, the TGF-β concentration is about 150 ng/mL to about 300 ng/mL, the VEGF concentration is about 200 pg/mL to about 400 pg/mL, the EGF concentration is about 1000 pg/mL to about 2000 pg/mL, the FGF concentration is about 300 pg/mL to about 600 pg/mL, and the HGF concentration is about 150 pg/mL to about 300 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL+/−25%, the fibrinogen concentration is 0.5-1.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 20 to about 40 ng/mL, the TGF-β concentration is about 150 ng/mL to about 300 ng/mL, the VEGF concentration is about 200 pg/mL to about 400 pg/mL, the EGF concentration is about 1000 pg/mL to about 2000 pg/mL, the FGF concentration is about 300 pg/mL to about 600 pg/mL, and the HGF concentration is about 150 pg/mL to about 300 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 60 mg/mL, the fibrinogen concentration is 0.5-1.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 20 to about 40 ng/mL, the TGF-β concentration is about 150 ng/mL to about 300 ng/mL, the VEGF concentration is about 200 pg/mL to about 400 pg/mL, the EGF concentration is about 1000 pg/mL to about 2000 pg/mL, the FGF concentration is about 300 pg/mL to about 600 pg/mL, and the HGF concentration is about 150 pg/mL to about 300 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 80 mg/mL to about 160 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 120 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 120 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 80 mg/mL to about 160 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 120 mg/mL+/−25%, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 120 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 80 mg/mL to about 160 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 80 mg/mL to about 160 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL+/−25%, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, and the PDGF-AB concentration is 40-80 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 80 mg/mL to about 160 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 40 to about 80 ng/mL, the TGF-β concentration is about 350 ng/mL to about 450 ng/mL, the VEGF concentration is about 400 pg/mL to about 800 pg/mL, the EGF concentration is about 2000 pg/mL to about 4000 pg/mL, the FGF concentration is about 600 pg/mL to about 1200 pg/mL, and the HGF concentration is about 300 pg/mL to about 1000 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL+/−25%, the fibrinogen concentration is 1.0-2.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 40 to about 80 ng/mL, the TGF-β concentration is about 350 ng/mL to about 450 ng/mL, the VEGF concentration is about 400 pg/mL to about 800 pg/mL, the EGF concentration is about 2000 pg/mL to about 4000 pg/mL, the FGF concentration is about 600 pg/mL to about 1200 pg/mL, and the HGF concentration is about 300 pg/mL to about 1000 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 120 mg/mL, the fibrinogen concentration is 1.0-2.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 40 to about 80 ng/mL, the TGF-β concentration is about 350 ng/mL to about 450 ng/mL, the VEGF concentration is about 400 pg/mL to about 800 pg/mL, the EGF concentration is about 2000 pg/mL to about 4000 pg/mL, the FGF concentration is about 600 pg/mL to about 1200 pg/mL, and the HGF concentration is about 300 pg/mL to about 1000 pg/mL

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 160 mg/mL to about 320 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 240 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 240 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 160 mg/mL to about 320 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 240 mg/mL+/−25%, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, and (b) human platelet proteins comprising PDGF-AB, wherein the total protein concentration of the composition is about 240 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 160 mg/mL to about 320 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL+/−25%.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 160 mg/mL to about 320 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL+/−25%, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, and the PDGF-AB concentration is 80-160 ng/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 160 mg/mL to about 320 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 80 ng/mL to about 160 ng/mL, the TGF-β concentration is about 500 ng/mL to about 1000 ng/mL, the VEGF concentration is about 800 pg/mL to about 1500 pg/mL, the EGF concentration is about 4000 pg/mL to about 6000 pg/mL, the FGF concentration is about 1200 pg/mL to about 3000 pg/mL, and the HGF concentration is about 1000 pg/mL to about 2500 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL+/−25%, the fibrinogen concentration is 2.0-5.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 80 ng/mL to about 160 ng/mL, the TGF-β concentration is about 500 ng/mL to about 1000 ng/mL, the VEGF concentration is about 800 pg/mL to about 1500 pg/mL, the EGF concentration is about 4000 pg/mL to about 6000 pg/mL, the FGF concentration is about 1200 pg/mL to about 3000 pg/mL, and the HGF concentration is about 1000 pg/mL to about 2500 pg/mL.

In some embodiments, a composition of the disclosure comprising the allogeneic human plasma and platelet derived product comprises (a) human plasma proteins comprising fibrinogen, albumin, and immunoglobulin, and (b) human platelet proteins comprising PDGF-AB, TGFβ, VEGF, EGF, FGF, HGF, or any combination thereof, wherein the total protein concentration of the composition is about 240 mg/mL, the fibrinogen concentration is 2.0-5.0 mg/mL, albumin is 60-70% w/w total protein, immunoglobulin is 10-20% w/w total protein, the PDGF-AB concentration is about 80 ng/mL to about 160 ng/mL, the TGF-β concentration is about 500 ng/mL to about 1000 ng/mL, the VEGF concentration is about 800 pg/mL to about 1500 pg/mL, the EGF concentration is about 4000 pg/mL to about 6000 pg/mL, the FGF concentration is about 1200 pg/mL to about 3000 pg/mL, and the HGF concentration is about 1000 pg/mL to about 2500 pg/mL.

In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition set forth in Example 31 produced by the method set forth in Example 31.

In some embodiments, the allogeneic human plasma and platelet derived product comprises a composition summarized in Table 5.

In some embodiments, the allogeneic human Plasma and Platelet derived product comprises a composition summarized in Table 6.

Method of Making Compositions

In some aspects, the disclosure provides methods for making compositions comprising an allogeneic human plasma and platelet derived product. In some embodiments, the methods described herein provide a highly concentrated and highly viscous composition comprising plasma and platelet derived proteins as described herein. In some embodiments, the method comprises providing a platelet suspension from one or more donors, lysing the platelets in the platelet suspension to release platelet proteins and generate a platelet extract comprising plasma proteins and platelet proteins, removing cell debris from the platelet extract to generate a purified platelet extract, and concentrating the platelet extract to generate the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises removal of red blood cells and white blood cells.

Illustrative methods are described below. In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering platelet suspensions, extracting platelet proteins and inactivating viruses, removing debris and viruses, concentrating the platelet extract, and diluting the allogeneic human plasma and platelet derived product as set forth in FIG. 1 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises, thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering platelet suspensions, extracting platelet proteins, inactivating viruses, and diluting the platelet extract, removing debris and viruses, concentrating the platelet extract, and diluting the allogeneic human plasma and platelet derived product as set forth in FIG. 2 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting, and filtering the platelet suspensions, extracting platelet proteins and inactivating viruses, removing debris and viruses, concentrating the platelet extract, and diluting the allogeneic human plasma and platelet derived product as set forth in FIG. 3 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting, and filtering the platelet suspensions, extracting platelet proteins, inactivating viruses, and diluting, removing debris and viruses, concentrating the platelet extract, and diluting the allogenic human plasma and platelet derived product as set forth in FIG. 4 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, removing albumin, diluting and filtering the platelet suspensions, extracting platelet proteins and inactivating viruses, removing debris and viruses, concentrating the platelet extract, and diluting the allogenic human plasma and platelet derived product as set forth in FIG. 5 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering the platelet suspensions, removing albumin, extracting platelet proteins and inactivating viruses, removing debris and viruses, concentrating the platelet extract, and diluting the allogeneic human plasma and platelet derived product as set forth in FIG. 6 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering the platelet suspensions, extracting platelet proteins, inactivating viruses, and removing albumin, removing debris and viruses, concentrating the platelet extract, and diluting the allogeneic human plasma and platelet derived product as set forth in FIG. 7 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering the platelet suspensions, extracting platelet proteins and inactivating viruses, removing debris and viruses, removing albumin, concentrating the platelet extract, and diluting the allogenic human plasma and platelet derived product as set forth in FIG. 8 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises thawing platelet suspensions, pooling platelet suspensions from at least 2 human donors, diluting and filtering the platelet suspensions, extracting platelet proteins and inactivating viruses, removing debris and viruses, concentrating the platelet extract, removing albumin, and diluting the allogenic human plasma and platelet derived product as set forth in FIG. 9 .

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises thawing platelet suspensions, centrifuging the platelet suspensions, pooling the platelet suspensions, filtering the platelet suspensions, extracting platelet proteins, centrifuging the platelet extract, filtering the platelet extract, removing viruses, concentrating the platelet extract, and filtering the allogeneic human plasma and platelet derived product as set forth in FIG. 26 .

Platelet Suspension Source

In some aspects, the compositions of the disclosure are obtained from processing of allogeneic human donor platelet suspensions from human whole blood or apheresis. In some embodiments, a platelet suspension comprises plasma and platelet cells. In some embodiments, platelet suspensions are obtained from whole blood. In some embodiments, platelets are obtained from whole blood using the buffy coat or platelet-rich plasma (PRP) technique. In the “PRP method”, anticoagulated whole blood is centrifuged using a soft spin under conditions validated to segregate red blood cells (RBC) from the upper half containing a platelet and plasma mixture, so called PRP. Platelets are then concentrated by hard spin centrifugation with validated acceleration and deceleration curves. The platelet suspension is left stationary at room temperature and then the concentrate is resuspended in plasma. In the “buffy coat” method, anticoagulated whole blood is centrifuged using a hard spin with validated acceleration and deceleration curves to separate “cell-free” plasma on the top layer, a middle layer called buffy coat (BC) and a red blood cells (RBC) bottom layer. The BC layer is transferred to a satellite bag. A small quantity of plasma is returned to the BC layer and gently mixed before again being subjected to light spinning centrifugation with validated acceleration and deceleration curves.

In some embodiments, platelet suspensions are obtained from apheresis. In some embodiments, apheresis comprises an extracorporeal medical device used in blood donation that separates the platelets and returns other portions of the blood to the donor. In some embodiments, apheresis comprises centrifugation to separate out platelets.

In some embodiments, the platelet suspensions are transfusable quality platelets. In some embodiments, platelet suspensions are tested under the Food and Drug Administration (FDA) Code of Federal Regulations (CFR) requirements. In some embodiments, the platelet suspensions are tested for adventitious agents. In some embodiments, the platelet suspensions are tested for sterility. In some embodiments, the platelet suspensions are tested for infections including, but not limited to, human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), syphilis, West Nile virus, and Chagas disease. In some embodiments, platelet suspensions are tested for bacterial infections.

In some embodiments, platelet suspensions are used immediately after being obtained. In some embodiments, platelet suspensions are stored at room temperature for future use. In some embodiments, platelet suspensions are stored at about 2 to about 8° C. In some embodiments, platelet suspensions are frozen at about −80° C. In some embodiments, platelet suspensions are stored in bags for future use. In some embodiments, platelet suspensions are stored for up to one year. In some embodiments, platelet suspensions are stored for up to 6 months.

In some embodiments, platelet suspensions are obtained from platelet bags. In some embodiments, the platelet bags are thawed at about 4 to about 25° C. In some embodiments, platelet bags are thawed at about 2 to about 8° C. In some embodiments, platelet bags are thawed at 4° C. In some embodiments, thawing occurs overnight. In some embodiments, thawing occurs in a refrigerator. In some embodiments, platelet bags are gently agitated in a refrigerator to thaw. In some embodiments, thawing occurs in a water bath. In some embodiments, platelet bags are gently agitated in a water bath to thaw. In some embodiments, platelet bags are subjecting to radiation to thaw. In some embodiments, platelet bags are gently agitated and subjected to radiation to thaw. In some embodiments, platelet bags are subjected to electromagnetic waves to thaw. In some embodiments, platelet bags are gently agitated and subjected to electromagnetic waves to thaw. In some embodiments, platelet bags are visually inspected for leakage prior to thawing. In some embodiments, platelet bags are visually inspected for leakage following thawing. In some embodiments, platelet bags are visually inspected before and after thawing.

In some embodiments, total protein concentration of the whole blood or platelet concentrate is evaluated. In some embodiments, a proteomics screen is used to evaluate functional serum proteins which include, but are not limited to, human serum albumin (©), fibrinogen, and alpha-2-macroglobulin. In some embodiments, a proteomics screen is used to evaluate functional platelet proteins which include but are not limited to basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor subunit A (PDGF-AA), platelet-derived growth factor subunit A and subunit B (PDGF-AB), platelet-derived growth factor subunit B (PDGF-BB), vascular endothelial growth factor (VEGF), transcription growth factor-β (TGF-β), interleukin 10 (IL-10), and interleukin 4 (IL-4). Methods for detecting and/or quantifying proteins are described herein.

In some embodiments, an anti-coagulant is included in the platelet suspension. In some embodiments, the anti-coagulant is an acid-citrate-dextrose solution. In some embodiments, the anti-coagulant is citrate. In some embodiments, the anti-coagulant is heparin.

In some embodiments, a clotting agent is not included in the platelet suspension. In some embodiments, a clotting agent is not utilized in the methods described herein.

Donor Demographics

In some aspects, methods for making the compositions described herein comprise obtaining platelet suspension from one or more donors. In some embodiments, the methods comprise pooling platelet suspension from two or more donors. In some embodiments, the methods comprising pooling platelet suspensions from about 10 to about 50 donors. In some embodiments, the methods comprising pooling platelet suspensions from about 50 to about 100 donors. In some embodiments, the methods comprise pooling platelet suspensions from about 100 to about 200 donors. In some embodiments, the methods comprise pooling platelet suspensions from at least 100 donors. In some embodiments, the methods comprise pooling platelet suspensions from at least 200 donors. In some embodiments, the methods comprise pooling platelet suspensions from 200 to 300 donors.

In some embodiments, a donor is an adult, e.g. 16-65 years old. In some embodiments, a donor is a young adult, e.g., 16-35 years old. In some embodiments, a donor is 16-40 years old. In some embodiments, a donor is at least 35 years old. In some embodiments, a donor is no more than 35 years old. Without wishing to be bound by theory, platelet suspensions from a young adult is expected to have a higher concentration of proteins of interest and a lower concentration of proinflammatory proteins relative to an older adult (e.g., over 35 years old). In some embodiments, a donor is 36-45 years old. In some embodiments, a donor is at least 45 years old. In some embodiments, a donor is older over 45 years old. In some embodiments, the donor is less than 65 years old. In some embodiments, platelet suspensions from two or more donors comprises at least one platelet suspension from a donor 16-35 years old, and at least one platelet suspension from a donor over 35 years old.

In some embodiments, a donor population comprises males. In some embodiments, a donor population comprises females. In some embodiments, a donor population comprises males and females.

In some embodiments, a donor is healthy as determined by a physician. In some embodiments, a donor does not have a disease or disorder. In some embodiments, a donor does not have a history of a disease or disorder. In some embodiments, a donor does not have a predisposition to a disease or disorder. In some embodiments, a donor does not have a family history of a disease or disorder. In some embodiments, a donor does not have genetic predisposition to a disease or disorder.

Pooling Platelet Suspensions

In some embodiments, platelet suspensions from more than one human subject donor are pooled. In some embodiments, platelet suspension from the same human subject donor are pooled. In some embodiments, platelet suspension from different human subject donors are pooled. As used herein, “pooling” refers to combining or accumulating two or more components (e.g., platelet suspensions) into one or more containers or vessels. In some embodiments, platelet suspensions are pooled before platelet proteins are extracted. In some embodiments, platelet suspensions are pooled before being diluted. In some embodiments, platelet suspensions are pooled while being diluted. In some embodiments, platelet suspensions are pooled before albumin is removed.

In some embodiments, the platelet suspension is pooled with a multi-head peristaltic pump. In some embodiments, the multi-head peristaltic pump is selected from, Masterflex®, Ismatec®, and BT100-1L. In some embodiments the platelet suspension is pooled with a single-use jacketed mixer with scale. In some embodiments, the single-use jacketed mixer is selected from, Xcellerex and Mobius. In some embodiments, the platelet suspension is pooled at a temperature of about 2 to about 25° C. In some embodiments, the platelet suspension is pooled at a temperature of about 2 to about 8° C. In some embodiments, the platelet suspension is pooled at a temperature of at least 2° C. In some embodiments, the platelet suspension is pooled at a temperature of at least 8° C. In some embodiments, the platelet suspension is pooled at temperature of at least 25° C. In some embodiments, the platelet suspension is pooled at a temperature no higher than 2° C. In some embodiments, the platelet suspension is pooled at a temperature no higher than 8° C. In some embodiments, the platelet suspension is pooled at temperature no higher than 25° C.

In some embodiments, the platelet suspensions are pooled prior to WBC and RBC removal. In some embodiments, a single-use jacketed mixer with scale is used to pool platelet suspensions. In some embodiments, a single-use jacketed mixer is selected from Xcellerex and Mobius.

Diluting and Blood Cell Removal

In some embodiments, methods for preparing an allogeneic human plasma and platelet derived product comprises removing white blood cells (WBCs) and red blood cells (RBCs). In some embodiments, to remove blood cells, the platelet suspension from whole blood or apheresis is diluted. Without wishing to be bound by theory, diluting the platelet suspension prevents clogging during removal of blood cells and reduces the loss of platelets and plasma proteins. In some embodiments, the platelet suspension is diluted prior to blood cell removal. In some embodiments, the platelet suspension is diluted during blood cell removal. In some embodiments the platelet suspension is diluted after blood cell removal.

In some embodiments, the platelet suspension is diluted in a suitable buffer. Suitable buffers include, but are not limited to, phosphate, citrate, EDTA, NaCl, KCl, MgCl 2 , CaCl 2 ), sucrose, glucose, trehalose, and PS20/80. In some embodiments, the buffer comprises phosphate at a concentration of about 20 to about 200 mM. In some embodiments, the buffer comprises phosphate at a concentration no greater than 20 mM. In some embodiments, the buffer comprises citrate at a concentration of about 15 to about 200 mM. In some embodiments, the buffer comprises citrate at a concentration no greater than 15 mM. In some embodiments, the buffer comprises EDTA at a concentration of about 0.3 to about 200 mM. In some embodiments, the buffer comprises EDTA at a concentration no greater than 0.3 mM. In some embodiments, the buffer comprises NaCl at a concentration of about 150 to about 200 mM. In some embodiments, the buffer comprises NaCl at a concentration no greater than 150 mM. In some embodiments, the buffer comprises KCl at a concentration of about 1 to about 200 mM. In some embodiments, the buffer comprises KCl at a concentration no greater than 1 mM. In some embodiments, the buffer comprises MgCl 2 at a concentration of about 1.3 to about 200 mM. In some embodiments, the buffer comprises MgCl 2 at a concentration no greater than 1.3 mM. In some embodiments, the buffer comprises CaCl 2 ) at a concentration of about 2.4 to about 200 mM. In some embodiments, the buffer comprises CaCl 2 ) at a concentration no greater than 200 mM. In some embodiments, the buffer comprises sucrose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises sucrose at a concentration no greater than 10 mM. In some embodiments, the buffer comprises glucose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises glucose at a concentration no greater than 10 mM. In some embodiments, the buffer comprises trehalose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises trehalose at a concentration no greater than 10 mM. In embodiments, the buffer comprises Polysorbate (PS20/80 at a concentration of about 0.025 to about 10%. In some embodiments, the buffer comprises PS20/80 at a concentration no greater than 0.025%. In some embodiments, the buffer pH is between about 4.0 and about 9.0. In some embodiments, the buffer pH is at least 4.0. In some embodiments, the buffer pH is at least 9.0. In some embodiments, the buffer pH is no higher than 4.0. In some embodiments, the buffer pH is no higher than 9.0.

In some embodiments, blood cell removal comprises filtering the platelet concentrate with a suitable filter. In some embodiments, a filter is made of polyvinylidene fluoride (PVDF), nylon, polyether sulfone (PES), polysulfone (PS), regenerated cellulose (RC), or Glass Fiber (GF). In some embodiments, a depth-filter is used to remove WBCs and RBCs. In some embodiments, a depth-filter is selected from, 3M:05SP01A, Sartoclear DL60, and Profile Star A030. In some embodiments, tangential flow filtration (TFF) is used to remove WBCs and RBCs. In some embodiments, the filter pore size is between about 0.1 μm and 50.0 μm. In some embodiments, the filter pore size is at least 0.1 μm. In some embodiments, the filter pore size is 0.1 μm. In some embodiments, the filter pore size is no bigger than 0.1 μm. In some embodiments, the filter pore size is at least 50.0 μm. In some embodiments, the filter pore size is 50.0 μm. In some embodiments, the filter pore size is no bigger than 50.0 μm. In some embodiments, the filter pore size is about 0.1 μm to about 5.0 μm. In some embodiments, the filter pore size is about 5 μm to about 10 μm. In some embodiments, the filter pore size is about 10 μm to about 20 μm. In some embodiments, the filter pore size is 10 μm to 25 μm. In some embodiments, the filter pore size is 25 μm to 50 μm. In some embodiments, the filter pore size is 30 μm to 40 μm. In some embodiments, the filter pore size is 35 μm to 50 μm.

WBCs exhibit different levels of rigidity at various temperatures. Specifically, WBCs are more rigid at cooler temperatures (e.g. 2-8° C.). Without wishing to be bound by theory, higher rigidity allows for more efficient filtration. Accordingly, in some embodiments, filtration occurs at 2-8° C. In some embodiments, filtration occurs at a temperature greater than 2° C. In some embodiments, filtration occurs at 2° C. In some embodiments, filtration occurs at 4° C. In some embodiments, filtration occurs at 10-20° C. In some embodiments, filtration occurs at 25-37° C. In some embodiments filtration occurs at 25° C. In some embodiments, filtration occurs at a temperature greater than 25° C. In some embodiments, filtration occurs at a temperature no greater than 37° C. In some embodiments, filtration occurs at 25-37° C. In some embodiments, filtration occurs at 30° C.

In some embodiments, the levels of WBCs and RBCs are quantified to validate that the blood cells have been removed or reduced from the platelet suspension. In some embodiments, cell count is used to determine WBCs and RBCs have been removed or reduced. In some embodiments, hemoglobin quantification is used to determine WBCs and RBCs have been removed or reduced. In some embodiments, DNA testing is used to determine WBCs have been removed. In some embodiments, RBC removal will be used to indicate removal of WBC. In some embodiments, RBC removal is determined by the amount of hemoglobin present.

In some embodiments, after filtering to remove blood cells, there is a 5-6 log reduction in white blood cell count. In some embodiments, the filtered platelet concentrate comprises 10 1 to 10 2 white blood cells.

Platelet Protein Extraction

Various methods known to those with ordinary skill in the art can be used to extract platelet proteins from platelets in a platelet suspension. In some aspects, the disclosure provides methods of extracting platelet proteins from platelets. In some embodiments, the platelet suspension is maintained under conditions sufficient to lyse the platelets to release platelet proteins and generate a platelet extract comprising plasma proteins and platelet proteins. In some embodiments, the platelet suspension is maintained under conditions sufficient to extract platelet proteins from the platelets and generate a platelet extract comprising plasma proteins and platelet proteins. In some embodiments, the platelet extract is stored at −80° C. until further processing to generate the compositions described herein.

Freeze-Thaw

In some embodiments, platelet proteins are extracted via freeze-thaw. In some embodiments, the platelet suspension is subjected to one freeze-thaw cycle to extract the platelet proteins. In some embodiments, the platelet suspension is subjected to two freeze-thaw cycles to extract the platelet proteins. In some embodiments, the platelet suspension is subjected to three freeze-thaw cycles to extract the platelet proteins. In some embodiments, the platelet suspension is subjected to at least two freeze-thaw cycles to extract the platelet proteins. In some embodiments, the platelet suspension is subjected to at least three freeze-thaw cycles to extract the platelet proteins.

In some embodiments, the platelet suspension is centrifuged to pelletize the platelets prior to the freeze-thaw cycle(s). In some embodiments, the platelet suspension is centrifuged at 3,000×g for 30 minutes at 22° C. In some embodiments, the platelet suspension is centrifuged a temperature of about 4 to 10° C. In some embodiments, the platelet suspension is centrifuged at a temperature of about 10 to 30° C. In some embodiments, the platelet suspension is centrifuged at a temperature of about 20 to 30° C. In some embodiments, the platelet suspension is centrifuged for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged for at least 30 minutes. In some embodiments, the platelet suspension is centrifuged for no longer than 30 minutes. In some embodiments, the platelet suspension is centrifuged at 3000×g. In some embodiments, the platelet suspension is centrifuged at a speed no faster than 3,000×g. In some embodiments, the platelet suspension is centrifuged at a speed at least 3,000×g. In some embodiments, the platelet suspension is centrifuged at a speed of about 1,000 to 2,000×g. In some embodiments, the platelet suspension is centrifuged at a speed of about 2,000 to 3,000×g. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 4 to 10° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 10 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 20 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 4 to 10° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 10 to 30° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at 3,000×g at a temperature of about 20 to 30° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 4 to 10° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 10 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 20 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 4 to 10° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 10 to 30° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed no higher than 3,000×g at a temperature of about 20 to 30° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least 3,000×g at a temperature of about 4 to 10° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least 3,000×g at a temperature of about 10 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least 3,000×g at a temperature of about 20 to 30° C. for about 10 to 20 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least than 3,000×g at a temperature of about 4 to 10° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least 3,000×g at a temperature of about 10 to 30° C. for about 20 to 30 minutes. In some embodiments, the platelet suspension is centrifuged at a speed of at least 3,000×g at a temperature of about 20 to 30° C. for about 20 to 30 minutes.

In some embodiments, after centrifugation the supernatant is removed, leaving a platelet pellet. In some embodiments, the platelet pellet is washed with a suitable buffer, e.g., phosphate-buffered saline (PBS). In some embodiments, the platelet pellet is concentrated to approximately one-tenth of the starting volume of platelets in the platelet suspension. In some embodiments, the freeze-thaw cycle comprises freezing at −80° C. In some embodiments, freezing occurs at −20° C. In some embodiments, freezing occurs at about −20 to about −196° C. In some embodiments, freezing occurs at a temperature of about −60 to −80° C. In some embodiments, freezing occurs at a temperature of about −40 to −80° C. In some embodiments, freezing occurs at a temperature of about −20 to −40° C. In some embodiments, freezing occurs at a temperature of at least −80° C. In some embodiments, freezing occurs at temperature no less than −80° C. In some embodiments, freezing occurs at a temperature of at least −20° C. In some embodiments, freezing occurs at a temperature no less than −20° C. In some embodiments, freezing occurs at a temperature lower than or equal to about −20° C., lower than or equal to about −79° C., lower than or equal to about −80° C., lower than or equal to about −81° C., lower than or equal to about −82° C., lower than or equal to about −83° C., lower than or equal to about −84° C., lower than or equal to about −85° C., lower than or equal to about −86° C., lower than or equal to about −87° C., lower than or equal to about −88° C., lower than or equal to about −89° C., lower than or equal to about −90° C., lower than or equal to about −100° C., lower than or equal to about −110° C., lower than or equal to about −120° C., lower than or equal to about −130° C., lower than or equal to about −140° C., lower than or equal to about −150° C., lower than or equal to about −160° C., lower than or equal to about −170° C., lower than or equal to about −180° C., lower than or equal to about −190° C. or about −196° C. In some embodiments, liquid nitrogen is used as a cryogenic means in each freeze cycle. In some embodiments, freezing with liquid nitrogen occurs at about −210° C.

In some embodiments, freezing occurs for about 30 minutes. In some embodiments, freezing occurs for no more than 30 minutes. In some embodiments, freezing occurs for no more than 1 hour. In some embodiments, freezing occurs for about 30 minutes to about 3 hours. In some embodiments, freezing occurs for about 1 to about 3 hours. In some embodiments, freezing occurs overnight.

In some embodiments, the freeze-thaw cycle comprises thawing at a temperature of about 2 to about 50° C. In some embodiments, the freeze-thaw cycle comprises thawing at about 2 to about 25° C. In some embodiments, the freeze-thaw cycle comprises thawing at about 25 to about 50° C. In some embodiments, the freeze-thaw cycle comprises thawing at 37±1° C. In some embodiments, thawing occurs in a dry bath. In some embodiments, thawing occurs in a water bath.

In some embodiments, after the last thaw, the platelet suspension is centrifuged at 4,500×g for 30 minutes at 20±1° C. In some embodiments, the platelet suspension is placed at 56±1° C. for 30 minutes and immediately cooled for at least 5 minutes on ice. In some embodiments, the platelet suspension is then centrifuged at 104×g for 15 minutes at 4±2° C. to eliminate precipitate.

In some embodiments, thawing occurs for about 5 minutes to about 24 hours. In some embodiments, thawing occurs for about 5 minutes. In some embodiments, thawing occurs for at least 30 minutes. In some embodiments, thawing occurs for about 6 hours. In some embodiments, thawing occurs overnight. In some embodiments, thawing occurs for about 16 hours. In some embodiments, thawing occurs for about 24 hours. In some embodiments, freezing occurs for no more than 30 minutes. In some embodiments, freezing occurs for about 30 minutes to about 3 hours.

Detergent-Buffer

In some embodiments, platelet proteins are extracted from platelets via incubation of the platelet suspension in one or more detergents. In some embodiments, the detergent is an anionic detergent. An exemplary anionic detergent includes sodium dodecyl sulphate (SDS). In some embodiments, an anionic detergent is SDS. In some embodiments, the detergent is a non-ionic detergent. Exemplary non-ionic detergents include Triton X-45, Triton X-100, Triton X-114, NP-40, Tween 20, and Tween 80. In some embodiments, a non-ionic detergent is Triton X-45. In some embodiments, a non-ionic detergent is Triton X-100. In some embodiments, a non-ionic detergent is Triton X-114. In some embodiments, a non-ionic detergent is NP-40. In some embodiments, a non-ionic detergent is Tween 20. In some embodiments, a non-ionic detergent is Tween 80. In some embodiments, the detergent is a zwitterionic detergent. Exemplary zwitterionic detergents include CHAPS and CHAPSO. In some embodiments, a zwitterionic detergent is CHAPS. In some embodiments, a zwitterionic detergent is CHAPSO. In some embodiments, a detergent is non-denaturing. Exemplary non-denaturing detergents include Triton X-45, Triton X-100, Triton X-114, and NP-40. In some embodiments, a detergent denatures proteins. In some embodiments, a detergent is a mild lysis agent. Exemplary mild lysis agents include Tween 20, Tween 80, CHAPS and CHAPSO. In some embodiments, a detergent is a strong lysis agent. An exemplary strong lysis agent is SDS. In some embodiments, the detergent is selected from SDS, Triton X-45, Triton X-100, Triton X-114, NP-40, Tween 20, Tween 80, CHAPS, and CHAPSO. In some embodiments, the detergent is SDS. In some embodiments, the detergent is Triton X-45. In some embodiments, the detergent is Triton X-100. In some embodiments, the detergent is Triton X-114. In some embodiments, the detergent is NP-40. In some embodiments, the detergent is Tween 20. In some embodiments, the detergent is Tween 80. In some embodiments, the detergent is CHAPS. In some embodiments, the detergent is CHAPSO. In some embodiments, the detergent is a cationic detergent. In some embodiments, the cationic detergent is ethyl trimethyl ammonium bromide.

In some embodiments, the detergent solution comprises sodium citrate. In some embodiments, the detergent solution comprises a chelating agent. In some embodiments, the chelating agent is EDTA. In some embodiments, the detergent solution comprises polysorbate 80 (PS80). In some embodiments, the detergent solution comprises sodium citrate, EDTA, and PS80.

In some embodiments, the platelet suspension is gently rocked in detergent. In some embodiments, the platelet suspension is incubated in the detergent for about 10 minutes to about 24 hours. In some embodiments, the platelet suspension is incubated in the detergent for about 10 minutes to about 1 hour. In some embodiments, the platelet suspension is incubated in the detergent for about 1 hour to about 6 hours. In some embodiments, the platelet suspension is incubated in the detergent for about 8 to about 10 hours. In some embodiments, the platelet suspension is incubated in the detergent overnight. In some embodiments, the platelet suspension is incubated in the detergent for about 12 hours to about 24 hours. In some embodiments, the platelet suspension is incubated in the detergent for no less than 10 minutes. In some embodiments, the platelet suspension is incubated in the detergent for no more than 24 hours.

In some embodiments, the platelet suspension is incubated in the detergent at a temperature of about 2 to about 40° C. In some embodiments, the platelet suspension is incubated in the detergent at a temperature of about 2 to about 8° C. In some embodiments, the platelet suspension is incubated in the detergent at a temperature of about 20 to about 30° C. In some embodiments, the platelet suspension is incubated in the detergent at a temperature of about 30 to about 40° C. In some embodiments, the platelet suspension is incubated in the detergent at a temperature no less than 2° C. In some embodiments, the platelet suspension is incubated in the detergent at a temperature no greater than 50° C.

In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 24 hours at a temperature of about 2 to 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 1 hour at a temperature of about 2 to 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 1 hour to about 6 hours at a temperature of about 2 to about 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 8 hours to about 10 hours at a temperature of about 4 to about 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 12 to about 24 hours at a temperature of about 4 to about 40° C.

In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 24 hours at a temperature of about 2 to 8° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 1 hour at a temperature of about 2 to 8° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 1 hour to about 6 hours at a temperature of about 2 to about 8° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 8 hours to about 10 hours at a temperature of about 2 to about 8° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 12 to about 24 hours at a temperature of about 2 to about 8° C.

In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 24 hours at a temperature of about 20 to 30° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 1 hour at a temperature of about 20 to 30° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 1 hour to about 6 hours at a temperature of about 20 to about 30° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 8 hours to about 10 hours at a temperature of about 20 to about 30° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 12 to about 24 hours at a temperature of about 20 to about 30° C.

In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 24 hours at a temperature of about 30 to 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 10 minutes to about 1 hour at a temperature of about 30 to 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 1 hour to about 6 hours at a temperature of about 30 to about 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 8 hours to about 10 hours at a temperature of about 30 to about 40° C. In some embodiments, the platelet suspension is gently rocked in detergent for about 12 to about 24 hours at a temperature of about 30 to about 40° C.

Osmotic Pressure

In some embodiments, platelet proteins are extracted from platelets by decreasing or increasing the osmolality of the surrounding fluid in the platelet suspension. In some embodiments, the osmolality of the surrounding fluid is decreased. In some embodiments, pl the osmolality of the surrounding fluid is increased. In some embodiments, salts are used to vary the osmolality of the surrounding fluid. In some embodiments, water is used to vary the osmolality of the surrounding fluid. In some embodiments, sugars are used to vary the osmolality of the surrounding fluid. In some embodiments, buffers are used to vary the osmolality of the surrounding fluid. In some embodiments, citrate is used to lower or increase the osmolality of the surrounding fluid. In some embodiments, the concentration of citrate is about 1 to about 200 mM. In some embodiments, the concentration of citrate is about 1 mM. In some embodiments, the concentration of citrate is about 20 mM. In some embodiments, the concentration of citrate is about 200 mM. In some embodiments, the concentration of citrate is at least 1 mM. In some embodiments, the concentration of citrate is no more than 1 mM. In some embodiments, the concentration of citrate is at least 20 mM. In some embodiments, the concentration of citrate is no more than 20 mM. In some embodiments, the concentration of citrate is at least 100 mM. In some embodiments, the concentration of citrate is no more than 100 mM. In some embodiments, the concentration of citrate is at least 200 mM. In some embodiments, the concentration of citrate is no more than 200 mM. In some embodiments, water is used to lower or increase the osmolality of the surrounding fluid. In some embodiments, citrate and water are used to lower or increase the osmolality of the surrounding fluid.

In some embodiments, the platelet suspension is diluted to lower the osmolality of the surrounding fluid. In some embodiments, the platelet concentrate is diluted 2-fold. In some embodiments, the platelet suspension is diluted 4-fold. In some embodiments, the platelet suspension is diluted 8-fold. In some embodiments, the platelet suspension is diluted at least 2-fold. In some embodiments, the platelet concentrate is diluted at least 8-fold.

In some embodiments, the osmolality ranges from about 0.01 to about 1,000 mOsm/kg. In some embodiments, the osmolality ranges from 0.01 to 5 mOsm/kg. In some embodiments, the osmolality ranges from 10 to 50 mOsm/kg. In some embodiments, the osmolality ranges from 100 to 250 mOsm/kg. In some embodiments, the osmolality ranges from 500 to 750 mOsm/kg. In some embodiments, the osmolality ranges from 750 to 1,000 mOsm/kg.

Sonication

In some embodiments, platelet proteins are extracted from platelets via sonication. In some embodiments, sonication comprises an ultrasonic bath to deliver high-frequency sound waves. In some embodiments, sonication comprises an ultrasonic probe to deliver high-frequency sound waves. In some embodiments, the high-frequency sound waves are at least 10 kHz. In some embodiments, the high-frequency sound waves are no greater than 10 kHz. In some embodiments, the high-frequency sound waves are at least 20 kHz.

Electroporation

In some embodiments, platelet proteins are extracted from platelets via electroporation in which a high-voltage electrical pulse is delivered. In some embodiments, the electric pulse ranges in magnitude from about 0.1 to about 10 kV. In some embodiments, the electric pulse ranges in magnitude from about 0.1 to about 5 kV. In some embodiments, the electric pulse ranges in magnitude from about 5 to about 10 kV. In some embodiments, the electric pulse ranges in resistance from about 1 to about 300Ω. In some embodiments, the electric pulse ranges in resistance from about 1 to about 50Ω. In some embodiments, the electric pulse ranges in resistance from about 50 to about 100Ω. In some embodiments, the electric pulse ranges in resistance from about 100 to about 200Ω. In some embodiments, the electric pulse ranges in resistance from about 200 to about 300Ω. In some embodiments, the electric pulse ranges in capacitance from about 1 to about 100 μF. In some embodiments, the electric pulse ranges in capacitance from about 1 to about 50 μF. In some embodiments, the electric pulse ranges in capacitance from about 50 to about 100 μF. In some embodiments, the electric pulse is administered for about 1 to about 20 milliseconds. In some embodiments, the electric pulse is administered for about 1 to about 10 milliseconds. In some embodiments, the electric pulse is administered for about 10 to about 20 milliseconds.

In some embodiments, an electric pulse with a magnitude of about 0.1 to about 10 kV is delivered for about 1 to about 20 milliseconds. In some embodiments, an electric pulse with a magnitude of about 0.1 to about 5 kV is delivered for about 1 to about 20 milliseconds. In embodiments, an electric pulse with a magnitude of about 5 to about 10 kV is delivered for about 1 to about 20 milliseconds. In some embodiments, an electric pulse with a magnitude of about 0.1 to about 10 kV is delivered for about 1 to about 10 milliseconds. In some embodiments, an electric pulse with a magnitude of about 0.1 to about 5 kV is delivered for about 1 to about 10 milliseconds. In embodiments, an electric pulse with a magnitude of about 5 to about 10 kV is delivered for about 1 to about 10 milliseconds. In some embodiments, an electric pulse with a magnitude of about 0.1 to about 10 kV is delivered for about 10 to about 20 milliseconds. In some embodiments, an electric pulse with a magnitude of about 0.1 to about 5 kV is delivered for about 10 to about 20 milliseconds. In embodiments, an electric pulse with a magnitude of about 5 to about 10 kV is delivered for about 10 to about 20 milliseconds.

Microfluidics

In some embodiments, platelet proteins are extracted from platelets via microfluidics in which platelets are passed through a microchannel at high pressure. In some embodiments, platelet proteins are extracted by one pass of the platelets through a microchannel. In some embodiments, platelet protein are extracted by at least one pass of the platelets through a microchannel. In some embodiments, platelets are subjected to pressure ranging from about 10,000 to about 50,000 PSI. In some embodiments, platelets are subjected to pressure ranging 10,000 to about 25,000 PSI. In some embodiments, platelets are subjected to pressure ranging from about 25,000 to about 50,000 PSI. In some embodiments, platelets are passed through a microchannel once at a pressure of about 10,000 to about 50,000 PSI. In some embodiments, platelets are passed through a microchannel once at a pressure of about 10,000 to about 25,000 PSI. In some embodiments, platelets are passed through a microchannel once at a pressure of about 25,000 to about 50,000 PSI. In some embodiments, platelets are passed through a microchannel at least once at a pressure of about 10,000 to about 50,000 PSI. In some embodiments, platelets are passed through a microchannel at least once at a pressure of about 10,000 to about 25,000 PSI. In some embodiments, platelets are passed through a microchannel at least once at a pressure of about 25,000 to about 50,000 PSI.

Combinatorial Approach to Platelet Protein Extraction

In some embodiments, a combinatorial approach is used to extract platelet proteins. In some embodiments, the combinatorial approach comprises methods selected from, but not limited to, freeze-thaw, buffer-detergent, osmotic pressure, sonication, electroporation, and microfluidics. In some embodiments, the combinatorial approach comprises at least two methods. In some embodiments, the combinatorial approach comprises at least three methods. In some embodiments, the combinatorial approach comprises at least four methods.

In some embodiments, freeze-thaw and detergent-buffer are used to extract platelet proteins. In some embodiments, osmotic pressure and detergent-buffer are used to extract platelet proteins. In some embodiments, sonication and detergent-buffer are used to extract platelet proteins. In some embodiments, electroporation and detergent-buffer are used to extract platelet proteins. In some embodiments, microfluidics and detergent-buffer are used to extract platelet proteins.

In some embodiments, freeze-thaw, detergent-buffer, and osmotic pressure are used to extract platelet proteins. In some embodiments, freeze-thaw, detergent-buffer, and sonication are used to extract platelet proteins. In some embodiments, freeze-thaw, detergent-buffer, and electroporation are used to extract platelet proteins. In some embodiments, freeze-thaw, detergent-buffer, and microfluidics are used to extract platelet proteins.

Purification

In some embodiments, after platelet proteins have been extracted from the platelets, thereby generating a platelet extract, the platelet extract is separated from cell debris and aggregates to generate a purified platelet extract. In some embodiments, cell debris is removed before and after extraction of platelet proteins. Removal of cell debris and aggregates can be performed with any standard technique known to those with ordinary skill in the art and described herein.

Micro-Filtration

In some embodiments, cell debris and aggregates are removed from the platelet extract via micro-filtration, in which the extract is passed through a filter at a defined flow rate. In some embodiments, a filter membrane is selected from polyvinylidene fluoride (PVDF), nylon, polyether sulfone (PES), polysulfone (PS), regenerated cellulose (RC), and glass fiber. In some embodiments, a filter pore size is 0.2 μm. In some embodiments, a filter pore size is at least 0.2 μm. In some embodiments, a filter pore size is no larger than 2 μm. In some embodiments, a filter pore size is between 0.2 and 2 μm. In some embodiments, the flow rate is between about 0.1 to about 50 L/hour. In some embodiments, the flow rate is between about 0.1 and about 5 L/hour. In some embodiments, the flow rate is between about 10 and about 25 L/hour. In some embodiments, the flow rate is between about 25 and about 50 L/hour.

In some embodiments, the extract is passed through a filter with a pore size of about 0.2 to about 2 μm at a flow rate of about 0.1 to about 50 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 to about 2 μm at a flow rate of about 0.1 to about 5 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 to about 2 μm at a flow rate of about 10 to about 25 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 to about 2 μm at a low rate of about 25 to about 50 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 μm at a flow rate of about 0.1 to about 50 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 μm at a flow rate of about 0.1 to about 5 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 μm at a flow rate of about 10 to about 25 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 0.2 μm at a low rate of about 25 to about 50 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 2 μm at a flow rate of about 0.1 to about 50 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 2 μm at a flow rate of about 0.1 to about 5 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 2 μm at a flow rate of about 10 to about 25 L/hour. In some embodiments, the extract is passed through a filter with a pore size of 2 μm at a low rate of about 25 to about 50 L/hour.

In some embodiments, micro-filtration comprises at least two cycles of filtration. Without wishing to be bound by theory, filtering with a larger pore size following by filtering with a smaller pore size will help prevent clogging and increase recovery. In some embodiments, micro-filtration comprises at least three cycles of filtration. In some embodiments, micro-filtration comprises filtering with a 2 μm filter followed by filtering with a 0.2 μm filter.

Depth-Filtration

In some embodiments, cell debris and aggregates are removed from the platelet extract via depth-filtration in which the extract is passed through a filtration medium at a defined flow rate. In some embodiments, a filtration medium is selected from cellulose, polypropylene, diatomaceous earth (DE), and non-DE in stacked disks. In some embodiments, a filtration medium is cellulose. In some embodiments, a filtration medium is polypropylene. In some embodiments, a filtration medium is DE. In some embodiments, a filtration medium is non-DE in stacked disks. In some embodiments, the flow rate is between about 0.1 to about 50 L/hour. In some embodiments, the flow rate is between about 0.1 and about 5 L/hour. In some embodiments, the flow rate is between about 10 and about 25 L/hour. In some embodiments, the flow rate is between about 25 and about 50 L/hour.

In some embodiments, the platelet extract is flowed over a cellulose filter at about 0.1 to about 5 L/hour. In some embodiments, the platelet extract is flowed over a cellulose filter at about 10 to about 25 L/hour. In some embodiments, the platelet extract is flowed over a cellulose filter at about 25 to about 50 L/hour. In some embodiments, the platelet extract is flowed over a polypropylene filter at about 0.1 to about 5 L/hour. In some embodiments, the platelet extract is flowed over a polypropylene filter at about 10 to about 25 L/hour. In some embodiments, the platelet extract is flowed over a polypropylene filter at about 25 to about 50 L/hour. In some embodiments, the platelet extract is flowed over a DE filter at about 0.1 to about 5 L/hour. In some embodiments, the platelet extract is flowed over a DE filter at about 10 to about 25 L/hour. In some embodiments, the platelet extract is flowed over a DE filter at about 25 to about 50 L/hour. In some embodiments, the platelet extract is flowed over a non-DE filter at about 0.1 to about 5 L/hour. In some embodiments, the platelet extract is flowed over a non-DE filter at about 10 to about 25 L/hour. In some embodiments, the platelet extract is flowed over a non-DE filter at about 25 to about 50 L/hour.

Centrifugation

In some embodiments, cell debris and aggregates are removed from the platelet extract via centrifugal force for a defined amount of time. In some embodiments, the platelet extract is centrifuged at about 50 to about 50,000×g. In some embodiments, the platelet extract is centrifuged at about 10 to about 10,000×g. In some embodiments, the platelet extract is centrifuged at about 10,000 to about 25,000×g. In some embodiments, the platelet extract is centrifuged at about 25,000 to about 50,000×g. In some embodiments, the platelet extract is centrifuged for about 1 to about 100 minutes. In some embodiments, the platelet extract is centrifuged for about 1 to about 60 minutes. In some embodiments, the platelet extract is centrifuged for about 60 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 50 to about 50,000×g for about 1 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 50 to about 50,000×g for about 1 to about 60 minutes. In some embodiments, the platelet extract is centrifuged at about 50 to about 50,000×g for about 60 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 10 to about 10,000×g for about 1 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 10 to about 10,000×g for about 1 to about 60 minutes. In some embodiments, the platelet extract is centrifuged at about 10 to about 10,000×g for about 60 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 10,000 to about 25,000×g for about 1 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 10,000 to about 25,000×g for about 1 to about 60 minutes. In some embodiments, the platelet extract is centrifuged at about 10,000 to about 25,000×g for about 60 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 25,000 to about 50,000×g for about 1 to about 100 minutes. In some embodiments, the platelet extract is centrifuged at about 25,000 to about 50,000×g for about 1 to about 60 minutes. In some embodiments, the platelet extract is centrifuged at about 25,000 to about 50,000×g for about 60 to about 100 minutes.

Viral Inactivation and Removal

In some embodiments, a method for preparing the allogeneic human plasma and platelet derived product described herein comprises viral inactivation and/or viral removal.

The term “viral inactivation” refers to maintenance of viruses in the platelet suspension or platelet extract, but the viruses are rendered non-viable e.g. by dissolving their lipid coat or by destroying their virion structure. The term “virus removal” refers to removal of viruses from the platelet suspension or platelet extract.

In some embodiments, viral inactivation occurs before removal of blood cells. In some embodiments, viral inactivation occurs after removal of blood cells. In some embodiments, viral inactivation occurs during removal of blood cells. In some embodiments, viral inactivation occurs during lysis of the platelets. In some embodiments, viral inactivation occurs during lysis of the platelets via buffer-detergent methods as described above. In some embodiments, viral inactivation occurs after platelet lysis. In some embodiments, viral inactivation occurs before dilution of the platelet suspension or platelet extract. In some embodiments, viral inactivation occurs after dilution of the platelet suspension or platelet extract. In some embodiments, viral inactivation occurs during dilution of the platelet suspension or platelet extract. In some embodiments, viral inactivation occurs before removal of cell debris and aggregates from the platelet extract. In some embodiments, viral inactivation occurs after removal of cell debris and aggregates from the platelet extract. In some embodiments, viral inactivation occurs during removal of cell debris and aggregates from the platelet extract.

In some embodiments, viral inactivation occurs with heat treatment. In some embodiments, heat inactivation is performed at a temperature of at least 45° C. In some embodiments, heat inactivation is performed at a temperature of no higher than 45° C. In some embodiments, heat inactivation is performed at a temperature of 45° C. In some embodiments, heat inactivation is performed for 1 hour. In some embodiments, heat inactivation is performed for at least 1 hour. In some embodiments, heat inactivation is performed at a temperature no higher than 45° C. for 1 hour. In some embodiments, heat inactivation is performed at a temperature of no higher than 45° C. for at least 1 hour. In some embodiments, heat inactivation is performed at a temperature of at least 45° C. for 1 hour. In some embodiments, heat inactivation is performed at a temperature of at least 45° C. for at least 1 hour. In some embodiments, heat inactivation is performed at a temperature of 45° C. for 1 hour. In some embodiments, heat inactivation is performed at a temperature of 45° C. for at least 1 hour. In some embodiments, a stabilizer can be added to platelet lysate to stabilize platelet proteins. In some embodiments, the stabilizer is sucrose. In some embodiments, the stabilizer is glycine. In some embodiments, the stabilizer is a combination of sucrose and glycine.

In some embodiments, viral inactivation occurs by varying pH. In some embodiments, the pH is lowered to inactivate viruses. In some embodiments, the pH is raised to inactivate viruses. In some embodiments, the pH is lowered to about 4. In some embodiments, the pH is lowered to about 3 to about 5. In some embodiments, the pH change lasts for about 6 to about 24 hours. In some embodiments, the pH change lasts for about 6 to about 16 hours. In some embodiments, the pH change lasts for about 16 to about 24 hours. In some embodiments, the pH is lowered to about 4 for about 6 to about 24 hours. In some embodiments, the pH is lowered to about 4 for about 6 to about 16 hours. In some embodiments, the pH is lowered to about 4 for about 16 to about 24 hours. In some embodiments, the pH is lowered to about 3 to about 5 for about 6 to about 24 hours. In some embodiments, the pH is lowered to about 3 to about 5 for about 6 to about 16 hours. In some embodiments, the pH is lowered to about 3 to about 5 for about 16 to about 24 hours.

In some embodiments, viral inactivation occurs with UV. In some embodiments, viral inactivation occurs with UV and riboflavin. In some embodiments, viral inactivation occurs with UV and riboflavin. In some embodiments, viral inactivation occurs with gamma radiation. In some embodiments, viral inactivation occurs with chemical treatment. Chemicals that can inactivate viruses include, but are not limited to, b-propiolactone, riboflavin, sulfites, and caprylate.

In some embodiments, viral removal occurs with nanofiltration. In some embodiments, the nanometer-scale filters can be any one of the following, Planova BioEX, Viresolve, Ultipore, Pegasus, or Virosart. In some embodiments, the nanometer-scale filter is a Planova S20N filter. In some embodiments, the nanofilter has a pore size of about 15 to about 75 nm. In some embodiments, the nanofilter has a pore size of less than 75 nm. In some embodiments, the nanofilter has a pore size of about 15 nm. In some embodiments, the nanofilter has a pore size of about 20 nm. In some embodiments, the nanofilter has a pore size of about 35 nm. In some embodiments, the nanofilter has a pore size of about 75 nm.

In some embodiments, viral removal occurs with filtration through a hollow fiber. In some embodiments, viral removal occurs with ion exchange chromatography. In some embodiments, viral removal occurs with affinity chromatography.

In some embodiments, viral removal occurs before removal of blood cells. In some embodiments, viral removal occurs after removal of blood cells. In some embodiments, viral removal occurs during removal of blood cells. In some embodiments, viral removal occurs during lysis of the platelets. In some embodiments, viral removal occurs during lysis of the platelets via buffer-detergent methods as described above. In some embodiments, viral removal occurs after platelet lysis. In some embodiments, viral removal occurs before dilution of the platelet suspension or platelet extract. In some embodiments, viral removal occurs after dilution of the platelet suspension or platelet extract. In some embodiments, viral removal occurs during dilution of the platelet suspension or platelet extract. In some embodiments, viral removal occurs before removal of cell debris and aggregates from the platelet extract. In some embodiments, viral removal occurs after removal of cell debris and aggregates from the platelet extract. In some embodiments, viral removal occurs during removal of cell debris and aggregates from the platelet extract.

In some embodiments, successful viral removal is determined by RT-qPCR. In some embodiments, RT-qPCR is used to detect viral nucleic acids.

Concentration

In some embodiments, the purified platelet extract described above is concentrated to generate the allogeneic human plasma and platelet derived product. In some embodiments, the platelet proteins and plasma proteins of the purified platelet extract are concentrated. Methods for concentrating proteins are known to those of skill in the art and described herein.

In some embodiments, concentration of the purified platelet extract occurs via buffer exchange and concentration. In some embodiments, buffer exchange removes components used throughout the method to maintain proteins in solution. In some embodiments, buffer exchanges removes components used during extraction of platelet proteins. In some embodiments, buffer exchange and concentration is carried out via a tangential flow filtration (TFF) system. In TFF, the solution of interest (e.g., purified platelet extract) is flowed over a membrane held by a module. In some embodiments, the module is selected from cassettes, hollow fiber, and ceramic. In some embodiments, the membrane is selected from modified polyethersulfone (mPES), regenerated cellulose, mixed cellulose ester, stabilized cellulose, phosphatidylserine (PS), and polyethersulfone (PES). In some embodiments, membranes are assembled into a filter assembly. In some embodiments, the membrane molecular weight cut off is between 1 kDa and 1,000 Kda. In some embodiments, the molecular weight cut off is between 500 kDa and 1,000 kDa. In some embodiments, the molecular weight cut off is between 750 kDa and 1,000 kDa. In some embodiments, the membrane molecular weight cut off is between 1 kDa and 500 kDa. In some embodiments, the molecular weight cut off is between 1 kDa and 30 kDa. In some embodiments, the molecular weight cut off is between 30 kDa and 60 kDa. In some embodiments, the molecular cut off weight is between 100 and 200 kDa. In some embodiments, the molecular cut off weight is between 250 and 500 kDa.

In some embodiments, the solution of interest is flowed over at least two filter assemblies. In some embodiments, the solution of interest is flowed over at least three filter assemblies. In some embodiments, the solution of interest is flowed over at least four filter assemblies. In some embodiments, the molecular weight cut off of a first filter assembly is different from the molecular weight cut off of a second filter assembly. In some embodiments, the molecular weight cut offs of every filter assembly is different.

The TFF system is conditioned with buffer prior to use. In some embodiments, conditioning with buffer wets the membrane. In some embodiments, conditions with buffer removes preservatives and storage solutions that may be present. Following conditioning, the solution of interest is introduced into the TFF system. A pump generates a tangential flow across the membrane, allowing solvent to pass through while the target molecules (e.g., purified platelet concentrate) is retained. As the feed solution flows across the membrane, water is driven through the membrane, creating a concentrated retentate on one side of the membrane. In some embodiments the flow rate is about 1 to about 50 L/hour. In some embodiments, the flow rate is at least 1 L/hour. In some embodiments, the flow rate is no more than 1 L/hour. In some embodiments, the flow rate is at least 50 L/hour. In some embodiments, the flow rate is no more than 50 L/hour. In some embodiments, the flow rate is about 1 to about 10 L/hour. In some embodiments, the flow rate is at about 10 to about 20 L/hour. In some embodiments, the flow rate is about 20 to about 30 L/hour. In some embodiments, the flow rate is about 30 to about 40 L/hour. In some embodiments, the flow rate is about 40 to about 50 L/hour. The retentate contains the concentrated target molecules, while the permeate (filtrate) contains the removed impurities and excess solvent/buffer. In some embodiments, TFF solvents and buffers are selected from phosphate, citrate, EDTA, NaCl, KCl, MgCl 2 , CaCl 2 ), sucrose, glucose, trehalose, polysorbate 20 (PS20) and polysorbate 80 (PS80). In some embodiments, the buffer comprises phosphate at a concentration of about 20 to about 200 mM. In some embodiments, the buffer comprises phosphate at a concentration no greater than 20 mM. In some embodiments, the buffer comprises citrate at a concentration of about 15 to about 200 mM. In some embodiments, the buffer comprises citrate at a concentration no greater than 15 mM. In some embodiments, the buffer comprises EDTA at a concentration of about 0.3 to about 200 mM. In some embodiments, the buffer comprises EDTA at a concentration no greater than 0.3 mM. In some embodiments, the buffer comprises NaCl at a concentration of about 150 to about 200 mM. In some embodiments, the buffer comprises NaCl at a concentration no greater than 150 mM. In some embodiments, the buffer comprises KCl at a concentration of about 1 to about 200 mM. In some embodiments, the buffer comprises KCl at a concentration no greater than 1 mM. In some embodiments, the buffer comprises MgCl 2 at a concentration of about 1.3 to about 200 mM. In some embodiments, the buffer comprises MgCl 2 at a concentration no greater than 1.3 mM. In some embodiments, the buffer comprises CaCl 2 at a concentration of about 2.4 to about 200 mM. In some embodiments, the buffer comprises CaCl 2 at a concentration no greater than 200 mM. In some embodiments, the buffer comprises sucrose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises sucrose at a concentration no greater than 10 mM. In some embodiments, the buffer comprises glucose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises glucose at a concentration no greater than 10 mM. In some embodiments, the buffer comprises trehalose at a concentration of about 10 to about 200 mM. In some embodiments, the buffer comprises trehalose at a concentration no greater than 10 mM. In embodiments, the buffer comprises PS20 at a concentration of about 0.025 to about 10%. In some embodiments, the buffer comprises PS20 at a concentration no greater than 0.025%. In embodiments, the buffer comprises PS80 at a concentration of about 0.025 to about 10%. In some embodiments, the buffer comprises PS80 at a concentration no greater than 0.025%.

In some embodiments, the buffer can be exchanged using a protein stabilizing buffer. In some embodiments, protein stabilizing buffers are selected from, phosphate, acetate, citrate, sulphate, glutamate, lactate, histidine, succinate, aspartic acid, tromethamine, and 2-(N-morpholino)ethanesulfonic acid (MES). In some embodiments, the protein stabilizing buffers include buffers that stabilize proteins and adjust tonicity and osmolarity. In some embodiments, protein stabilizing buffers comprise sucrose, dextrose, trehalose, sorbitol, mannitol, maltose, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, or any combination thereof.

The concentrated and diafiltrated target molecules are collected as the final retentate. The product can then be further processed or formulated for the subsequent downstream processing steps.

Removing Plasma Proteins

In some embodiments, plasma proteins are removed from the allogeneic human plasma and platelet derived product. In some embodiments, the plasma proteins are removed after pooling. In some embodiments, plasma proteins are removed before platelet protein extraction. In some embodiments, plasma proteins are removed after platelet protein extraction. In some embodiments, plasma proteins are removed before concentration. In some embodiments, plasma proteins are removed after concentration.

In some embodiments, albumin is removed. In some embodiments, immunoglobulins are removed. In some embodiments, albumin and immunoglobulins are removed. In some embodiments, albumin and immunoglobulins are removed simultaneously. In some embodiments, the same affinity column is used to remove albumin and immunoglobulins. In some embodiments, different affinity columns are used in parallel to remove albumin and immunoglobulins.

Concentration Adjustment and Sterile Filtration

In some embodiments, the allogeneic human plasma and platelet derived product is sterile filtered. Filtration can be performed with any standard technique known to those with ordinary skill in the art. In some aspects, the disclosure provides methods of sterile filtering concentrated platelet lysate.

In some embodiments, the allogeneic human plasma and platelet derived product is diluted to a desired concentration. In some embodiments, the allogeneic human plasma and platelet derived product is concentrated to a desired concentration. In some embodiments, the desired concentration is about 20 to about 500 mg/mL. In some embodiments, the desired concentration is about 50 to about 500 mg/mL. In some embodiments, the desired concentration is greater than 50 mg/mL and less than or about 500 mg/mL. In some embodiments, the desired concentration is about 50 to about 80 mg/mL. In some embodiments, the desired concentration is about 80 to about 160 mg/mL. In some embodiments, the desired concentration is about 160 to about 320 mg/mL. In some embodiments, the desired concentration is about 70 to about 250 mg/mL. In some embodiments, the desired concentration is about 70 to about 150 mg/mL. In some embodiments, the desired concentration is about 150 to about 250 mg/mL. In some embodiments, the desired concentration is about 150 to about 200 mg/mL. In some embodiments, the desired concentration is at least 150 mg/mL. In some embodiments, the desired concentration is at least 200 mg/mL. In some embodiments, the desired concentration is less than about 500 mg/mL. in some embodiments, the desired concentration is greater than 50 mg/mL.

In some embodiments, the allogeneic human plasma and platelet derived product is passed through a filter with a pore size of about 0.1 to about 0.22 μm. In some embodiments, the filter pore size is no bigger than 0.22 μm. In some embodiments, the filter pore size is at least 0.1 μm. In some embodiments, the filter pore size is about 0.1 to about 0.2 μm. In some embodiments, the filter material is selected from polyvinylidene fluoride (PVDF), nylon, polyether sulfone (PES), polysulfone (PS), regenerated cellulose (RC), and glass fiber.

Lyophilization

In some embodiments, the allogeneic human plasma and platelet derived product is lyophilized. Lyophilization is advantageous at least because the resulting substance is easier to store, can be kept in a small place, is easier to handle, can be applied in a formulation (e.g., in a dry powder, an ointment, a suspension, a solution, a gel, a cream or a biocompatible, synthetic or natural solid matrix) chosen according to the circumstances, can be administered at an optimal dose, normally has a longer shelf life, and can easily be screened for the most active preparation.

In some embodiments, lyophilization comprises freezing the allogeneic human plasma and platelet derived product. In some embodiments, freezing occurs at a temperature lower than −10° C. In some embodiments, freezing occurs at a temperature lower than −20° C. In some embodiments, freezing occurs at a temperature lower than −60° C. In some embodiments, freezing occurs at a temperature lower than 80° C. In some embodiments, freezing occurs for at least 30 minutes. In some embodiments, freezing occurs for about 1 to about 3 hours. In some embodiments, freezing occurs for about 6 to about 12 hours. In some embodiments, freezing occurs overnight. In some embodiments, freezing occurs for no more than 24 hours.

In some embodiments, lyophilization comprises drying the allogeneic human plasma and platelet derived product. In some embodiments, a drying is facilitated by a vacuum. In some embodiments, lyophilization comprises reducing the water concentration of the allogeneic human plasma and platelet derived product. In some embodiments, reducing the water concentration prevents biological or chemical reactions.

Exemplary Methods of Making the Compositions

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects with a buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via tangential flow filtration (TFF). In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, (b) removing cell debris and aggregates from the platelet extract, thereby generating purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the methods comprise (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donors via freeze-thaw, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the methods comprise (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises extracting platelet proteins from plasma and platelets from one or more human donors via freeze-thaw, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing the cell debris and aggregates from the platelet extract via filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the methods comprise (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing the cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing the cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract, and (c) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing the cell debris and aggregates from the platelet extract via centrifugation and filtration, thereby generating a purified platelet extract and (c) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via detergent-buffer, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract and (d) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis via dilution, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via detergent-buffer, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) obtaining and diluting a platelet suspension from whole blood or apheresis, (b) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (c) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the an allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) clarifying the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a nylon filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet from plasma and platelets from one or more human donor subjects, via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via TFF, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract via spin filters, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) concentrating the purified platelet extract, thereby generating an allogeneic human plasma and platelet derived product, and (d) sterile filtering the allogeneic human plasma and platelet derived product with a PES filter.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting the platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via TFF. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via spin filters.

In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via freeze-thaw, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via buffer-detergent, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects via osmotic pressure, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract. In some embodiments, the method comprises (a) extracting platelet proteins from plasma and platelets from one or more human donor subjects, thereby generating a platelet extract, (b) removing cell debris and aggregates from the platelet extract via centrifugation, thereby generating a purified platelet extract, (c) diluting the purified platelet extract, and (d) concentrating the purified platelet extract via TFF.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein extracting the platelet proteins comprises freeze-thaw, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension and extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension and extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris via centrifugation and filtration, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension and extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris via centrifugation and filtration, wherein filtration also removes viruses, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension and extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris via centrifugation and filtration, wherein filtration also removes viruses, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, and (d) concentrating the purified platelet extract via TFF, thereby generating the allogeneic human plasma and platelet derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product comprises (a) providing a platelet suspension from one or more donor human subjects, wherein the platelet suspension comprises plasma and platelets, and wherein plasma comprises plasma proteins, (b) maintaining the plasma and platelets under conditions appropriate to extract platelet proteins from the platelets, wherein an anti-coagulant is added to the platelet suspension and extracting the platelet proteins comprises buffer-detergent, thereby generating a platelet extract comprising the plasma proteins and the platelet proteins, (c) separating the platelet extract from cell debris via centrifugation and filtration, wherein filtration also removes viruses, thereby generating a purified platelet extract comprising the plasma proteins and the platelet proteins, (d) concentrating the purified platelet extract via TFF, and (e) filtering the purified platelet extract, thereby generating the allogenic human platelet and plasma derived product.

In some embodiments, a method for preparing a pharmaceutical composition comprising an allogenic human plasma and platelet derived product comprises (a) thawing platelet bags, thereby generating a platelet suspension, (b) centrifuging the platelet suspension, (c) concentrating the platelet suspension, (d) filtering the platelet suspension, (e) extracting platelet proteins from plasma and platelets, thereby generating a platelet extract, (f) centrifuging the platelet extract, (g) filtering the platelet extract, (h) inactivating and removing viruses, (i) concentrating the platelet extract, thereby generating concentrated purified platelet extract and (j) filtering the concentrated purified platelet extract, thereby generating the allogeneic human platelet and plasma derived product.

Pharmaceutical Compositions and Methods of Use

In some aspects, the disclosure provides a pharmaceutical composition comprising an allogeneic human plasma and platelet derived product described herein. In some embodiments, the pharmaceutical composition is formulated for injection. In some embodiments, the pharmaceutical composition is formulated for epidural injection. In some embodiments, the pharmaceutical composition is formulated for intraarticular injection. In some embodiments, the pharmaceutical composition is formulated for intrathecal injection. In some embodiments, the pharmaceutical composition is formulated for intravenous injection. In some embodiments, the pharmaceutical composition is formulated for intramuscular injection. In some embodiments, the pharmaceutical composition is formulated for subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intraosseous administration. In some embodiments, the pharmaceutical composition is formulated for bursal injection. In some embodiments, the pharmaceutical composition is formulated for injection into a tendon. In some embodiments, the pharmaceutical composition is formulated for injection into a ligament. In some embodiments, the pharmaceutical composition is formulated for sub-retinal injection. In some embodiments, the pharmaceutical composition is formulated for intravitreal injection. In some embodiments, the pharmaceutical composition is formulated for suprachoroidal injection. In some embodiments, the pharmaceutical composition is formulated as an eye drop. In some embodiments, the pharmaceutical composition is formulated as a bioadhesive. In some embodiments, the pharmaceutical composition is formulated as a gel. In some embodiments, the pharmaceutical composition is formulated as a gel within a bandage. In some embodiments, the pharmaceutical composition is formulated as a hydrocolloid bandage.

In some embodiments, the pharmaceutical composition is formulated so that it is suitable for self-administration. In some embodiments, the pharmaceutical composition is formulated for administration via a vial and syringe, a prefilled syringe, or a spring-driven prefilled pen or autoinjector.

In some embodiments, the pharmaceutical composition is prepared with a physiologically acceptable carrier or diluent. Suitable carriers or excipients are, for example, water, saline, dextrose, glycerol, of the like and combinations thereof. Lyophilized compositions are typically rehydrated before therapeutic use. In some embodiments, the pharmaceutical composition comprises carriers or excipients suitable for delivery to the central nervous system. Formulation strategies for epidural or intrathecal administration are described at least by Calias, P. et al. ( Pharmacology & therapeutics vol. 144, 2 (2014): 114-22), incorporated herein by this reference.

In some embodiments, the pharmaceutical composition forms a depot at the site of injection, such that the platelet proteins and plasma proteins are maintained at the site of injection for a period of time.

In some embodiments, the disclosure provides a method for treating pain, comprising administering a composition comprising the allogenic human plasma and platelet derived product described herein.

For injuries such as traumatic injuries or open wounds, local direct delivery of high concentration plasma and platelet protein solution holds promise in acceleration of wound healing. Autologous platelet rich plasma has been discussed in this context and its promise has been noted (Everts, Peter A et al. International journal of molecular sciences vol. 25, 14 7914. 19 Jul. 2024, doi:10.3390/ijms25147914 and Shariati, Aref et al. Annals of clinical microbiology and antimicrobials vol. 20, 1 40. 27 May 2021, doi:10.1186/s12941-021-00442-x). Without wishing to be bound by theory, the compositions described herein would provide a therapeutic option immediately available without the need to rely on the patient and the preparation of their own blood. Furthermore, when combined with formulation excipients and/or when adhered to a bandage system a high concentration plasma and platelet protein solution could also provide effective antimicrobial protection and action (Ahmadpoor, Fatemeh et al. ACS applied bio materials vol. 8, 1 (2025): 152-165. doi:10.1021/acsabm.4c00788).

Accordingly, in some embodiments, the disclosure provides a method for treating traumatic injury or open wounds, comprising administering a composition comprising the allogenic human plasma and platelet derived product described herein. In some embodiments, the traumatic injury or open wound is a burn injury.

Sub-retinal injection of cord blood platelet rich plasma was explored clinically for the treatment of geographic atrophy (GA) associated with dry age-related macular degeneration (d-AMD) where the results supported safety, but improved outcomes were not demonstrated in the trial (Rizzo, Stanislao et al. Ophthalmology science vol. 4, 6 100476. 24 Jan. 2024, doi:10.1016/j.xops.2024.100476). Furthermore, evidence from mouse models suggest that a product rich in growth factors would be beneficial for treatment of age-related macular degeneration (Anitua, Eduardo et al Medicina ( Kaunas, Lithuania ) vol. 60, 12 2036. 10 Dec. 2024, doi:10.3390/medicina60122036). In addition, autologous platelet rich plasma has shown promise in acceleration of healing in corneal defects (Alizadeh, Shaban et al. Journal of ophthalmic & vision research vol. 14, 2 (2019): 131-135. doi:10.4103/jovr.jovr_279_17). Without wishing to be bound by theory, the compositions described herein may provide higher doses of active proteins and lead to greater and more measurable therapeutic effects.

In some embodiments, the disclosure provides a method for treating ophthalmic indications, comprising administering a composition comprising the allogenic human plasma and platelet derived product described herein. In some embodiments, an ophthalmic indication is age-related macular degeneration. In some embodiments, an ophthalmic indication is diabetic retinopathy.

In some embodiments, the disclosure provides a method for treating an orthopedic indication, comprising administering a composition comprising the allogeneic human plasma and platelet derived product described herein. In some embodiments, the orthopedic indication is back pain. In some embodiments, the orthopedic indication is painful lumbosacral radiculopathy. In some embodiments, the orthopedic injury is a spinal cord injury. In some embodiments, an orthopedic injury is osteoarthritis. In some embodiments, an orthopedic injury is ligament laxity. In some embodiments, an orthopedic injury is a rotator cuff injury. In some embodiments, an orthopedic injury is a muscle injury. In some embodiments, the orthopedic indication is joint pain. In some embodiments, the orthopedic indication is knee pain. In some embodiments, the orthopedic indication is shoulder pain. In some embodiments, the orthopedic indication is carpal tunnel.

Exemplary Treatment Methods I

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering the pharmaceutical composition via epidural injection. In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering the pharmaceutical composition via intrathecal injection.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 pg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating painful lumbosacral radiculopathy in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering the pharmaceutical composition via epidural injection. In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering the pharmaceutical composition via intrathecal injection.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating back pain in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering the pharmaceutical composition via epidural injection. In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering the pharmaceutical composition via intrathecal injection.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via epidural injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating spinal cord injury in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering the pharmaceutical composition via intrathecal injection. In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering the pharmaceutical composition via intraosseous injection.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intraosseous injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intraosseous injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intraosseous injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intraosseous injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intraosseous injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating osteoarthritis in a subject in need thereof, comprising administering a pharmaceutical composition via intrathecal injection to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering the pharmaceutical composition via injection into the injured ligament.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering a pharmaceutical composition via injection into the injured ligament to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering a pharmaceutical composition via injection into the injured ligament to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering a pharmaceutical composition via injection into the injured ligament to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering a pharmaceutical composition via injection into the injured ligament to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating ligament laxity in a subject in need thereof, comprising administering a pharmaceutical composition via injection into the injured ligament to a subject, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering the pharmaceutical composition via intraarticular injection. In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering the pharmaceutical composition via injection into the rotator cuff tendon. In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering the pharmaceutical composition via bursal injection.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via intraarticular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via intraarticular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via intraarticular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via intraarticular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via intraarticular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the rotator cuff tendon, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the rotator cuff tendon, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the rotator cuff tendon, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the rotator cuff tendon, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the rotator cuff tendon, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via bursal injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via bursal injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via bursal injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via bursal injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating rotator cuff injury in a subject in need thereof, comprising administering a pharmaceutical composition via bursal injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering the pharmaceutical composition via intramuscular injection. In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering the pharmaceutical composition via injection into the local muscle tear region.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via intramuscular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via intramuscular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via intramuscular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via intramuscular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via intramuscular injection, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the local muscle tear region, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising platelet derived growth factor (PDGF)-AB, PDGF-AA, PDGF-BB, transforming growth factor beta (TGFβ1, TGFβ2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), b-fibroblast growth factor (FGF), epidermal growth factor (EGF) and hepatocyte growth factor (HGF), wherein the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the local muscle tear region, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the local muscle tear region, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the local muscle tear region, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating muscle injury in a subject in need thereof, comprising administering a pharmaceutical composition via injection to the local muscle tear region, wherein the pharmaceutical composition comprises an allogeneic human plasma and platelet derived product comprising:

(a) human plasma proteins comprising albumin, globulins, and fibrinogen; and (b) human platelet proteins comprising PDGF-AB, PDGF-AA, PDGF-BB, TGFβ1, TGFβ2, BDNF, VEGF, FGF, EGF and HGF, wherein, the total protein concentration of the composition is greater than 50 mg/mL and less than or about 500 mg/mL, wherein the concentration of PDGF-AB is greater than 50 pg/mL and less than 1,000 pg/mL, wherein the concentration of fibrinogen is about 20 μg/mL to about 10 mg/mL, and wherein the viscosity of the composition is about 1 to about 40 cP.

In some embodiments, the disclosure provides a method for treating joint pain in a subject in need thereof, comprising administering the pharmaceutical composition via intraosseous injection. In some embodiments, the discl